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“(…) Once he got home Rieux telephoned his colleague Dr Richard,  
one of the leading doctors in the town. 
‘No,’ Richard said. ‘I haven’t seen anything out of the ordinary.’ 
‘Not high temperature with local inflammation?’ 
‘Well, yes, as it happens: two cases with very enlarged lymph nodes.’ 
‘Abnormally so?’ 
‘Huh!’ said Richard. ‘You know … What’s normal?’ (…)” 
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Gastroenteritis is a common term for acute infection of the gastrointestinal tract and 
includes several conditions and specific infections. Gastroenteritis has to a great extent 
caused disease and death in humans through our history. Even the very foundation of 
epidemiology can be traced back to John Snow's work on identifying drinking water as 
source of the cholera epidemic in London in 1854. Gastroenteritis still occurs frequently 
in the community, but most people in our part of the world experience self-limiting 
symptoms and therefore only a small proportion seek the health care services. Of those 
seeking medical attention, only a few submit stool samples for microbiological 
diagnostics, and only those who are diagnosed with a notifiable microbe are included in 
the statistics of the notification systems of infectious diseases. The clinical features of 
gastroenteritis vary from asymptomatic cases to fatal disease, but diarrhea is common in 
cases who develop symptoms.   
The clinical features in the individual gastroenteritis patient can give a hint as to whether 
there is a viral or bacterial cause. Correspondingly, using existing knowledge about 
seasonal variation and the epidemiology of the specific infections may give an indication 
of probable microbiological cause in gastroenteritis patients at group level. This is useful 
knowledge because laboratory verified diagnoses are rare. Our study of consultations for 
gastroenteritis in Norwegian primary care during a 10-year period shows a contact pattern 
similar to what characterizes viral gastroenteritis: Most consultations took place in the 
winter and children and young adults dominated among the patients. The findings 
contribute to increased knowledge of the normal situation regarding gastroenteritis 
patients’ use of health care services.  
Since antibiotics became widely available in the years following World War II, antibiotic 
treatment has been central to the treatment of many infectious diseases. Gastroenteritis 
has been an exception, both because most are viral and because antibiotics only to a small 
extent have been shown to shorten the course of the disease and relieve symptoms also in 





represent a growing concern in a European and global context, although the current 
situation in Norway is more favorable. Transmission between animals and humans, either 
directly or indirectly via food, makes resistance in zoonoses and food-borne microbes 
particularly challenging. Our study of antibiotic use in gastroenteritis in the Norwegian 
primary health care service over a 10-year period shows that antibiotics are rarely used 
compared with other countries. Further, there has been an even more favorable 
development after 2012 with a decrease in the use of resistance-driving antibiotics such as 
fluoroquinolones and macrolides.  
Gastroenteritis tends to appear as outbreaks of various magnitude and public health 
importance. The outbreaks occur and spread either via direct contact between humans, 
directly between humans and animals, or as food-borne outbreaks where the microbe 
spreads to humans via food or drinking water. Gastroenteritis caused by the foodborne 
infection campylobacteriosis is an example of the latter, and in June 2019, more than 
1 500 in the community became acutely ill during a major waterborne outbreak of 
Campylobacter infection in Askøy. Our population-based study of acute gastroenteritis 
during the outbreak shows a broader spectrum of symptoms, with less bloody stools and 
more tiredness and joint pain than previously described in laboratory-verified sporadic 
cases of Campylobacter infection. The study sheds light on the cases of gastroenteritis 
that occur in the interface between how they appear in the community, in the health care 







Gastroenteritter er en fellesbetegnelse på akutt infeksjon i mage-tarm-kanalen og omfatter 
flere tilstander og spesifikke infeksjoner. Gastroenteritter har i stor grad forårsaket 
sykdom og død hos mennesker opp igjennom vår historie, og selve opphavet til faget felt-
epidemiologi føres tilbake til John Snows arbeid med å identifisere drikkevann som kilde 
til kolera-epidemien i London i 1854. Stadig forekommer gastroenteritter hyppig i 
befolkningen, men de fleste i Norge opplever selvbegrensende plager og derfor oppsøker 
kun en liten andel lege. Av de som søker lege blir et fåtall undersøkt med avføringsprøve 
for mikrobiologisk diagnostikk, og kun de som får påvist en meldingspliktig mikrobe 
inngår i statistikken til meldesystemene for infeksjonssykdommer. Sykdomsbildet ved 
gastroenteritt varierer fra asymptomatisk til dødelig sykdom, men diare er vanlig hos de 
fleste som utvikler symptomer.  
Det kliniske bildet hos den enkelte gastroenterittpasient kan gi et hint om det foreligger en 
viral eller bakteriell årsak. I tillegg kan bruk av eksisterende kunnskap om 
sesongvariasjon og epidemiologi til de spesifikke infeksjonene si noe om sannsynlige 
agens hos pasienter på gruppenivå. Dette er nyttig kunnskap fordi man sjelden har 
laboratorieverifiserte diagnoser. Vår studie av legekonsultasjoner for gastroenteritt i norsk 
primærhelsetjeneste over en 10-års periode viser et kontaktmønster som likner det som 
kjennetegner virale gastroenteritter, hvor flest konsultasjoner fant sted på vinteren og hvor 
barn og unge voksne dominerte blant pasientene. Resultatene bidrar til en økt forståelse 
av normalsituasjonen for legesøkning ved gastroenteritter.  
Etter at antibiotika ble allment tilgjengelig i tiden etter andre verdenskrig, har de stått 
sentralt i håndteringen av mange infeksjonssykdommer. Gastroenteritter har vært et 
unntak, både fordi de fleste er viralt betinget og fordi antibiotika i liten grad er vist å 
forkorte sykdomsforløp og lindre symptomer også for de fleste tilfellene av bakterielle 
gastroenteritter. Antibiotika-resistens hos bakterier som gir gastroenteritt er et økende 
problem i europeisk og global sammenheng, selv om situasjonen i Norge foreløpig er 





næringsmidler, gjør resistensproblematikken ved zoonoser og næringsmiddelbårne 
mikrober særlig utfordrende. Vår studie av antibiotikabruk ved gastroenteritter i norsk 
primærhelsetjeneste over en 10-års periode viser at antibiotika brukes sjelden 
sammenliknet med andre land. Det har vært en ytterligere gunstig utvikling etter 2012 
med nedgang i bruk av særlig resistensdrivende antibiotika som fluorokinoloner og 
makrolider. 
Gastroenteritter har en tendens til å opptre i større eller mindre utbrudd av ulik 
samfunnsmedisinsk betydning. Utbruddene oppstår og spres enten via direkte kontakt 
mennesker imellom, direkte mellom mennesker og dyr, eller som næringsmiddelbårne 
utbrudd der mikroben spres til mennesker via mat eller drikkevann. Gastroenteritt 
forårsaket av den næringsmiddelbårne infeksjonen campylobacteriose er et eksempel på 
sistnevnte, og i juni 2019 ble mer enn 1 500 personer akutt syke under et stort vannbårent 
utbrudd av Campylobacter-infeksjon på Askøy. Vår populasjonsstudie av akuttforløpet 
ved gastroenteritt under dette utbruddet viser et bredere spektrum av symptomer, med 
mindre blodig avføring og mer tretthet og leddsmerter, enn det som tradisjonelt er 
beskrevet for laboratoriebekreftede sporadiske Campylobacter-tilfeller. Studien belyser de 
tilfellene av gastroenteritter som opptrer i grenselandet mellom slik de forekommer i 
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1.1.1 Definitions and clinical features 
Many different terms are used when referring to the condition that reflects an acute 
inflammation of the gastrointestinal tract which is caused by various microbes or toxins. 
In the literature of studies from primary care or population-based studies, terms such as 
‘diarrheal disease’ (1, 2), ‘infectious intestinal disease’ (3), ‘diarrheal disease’ (4), ‘acute 
gastrointestinal infections’ (5-8), ‘diarrhea’ (9), ‘acute diarrhea’ (10, 11), and 
‘gastroenteritis’ (12-14) are used for this condition, of which the latter is used in this 
thesis.  
Gastroenteritis is a generic term referring to various clinical characteristics (such as 
‘winter-vomiting disease’, ‘dysentery’, ‘tourist diarrhea’, ‘food poisoning’), and specific 
infections with an identified microbe (e.g. ‘campylobacteriosis’ and ‘giardiasis’). There 
exists no common definition of gastroenteritis, but there has been suggested a common 
symptom-based definition of a gastroenteritis case: An individual who experiences ≥ 3 
loose stools, or any vomiting, in 24 hours, excluding cases where these symptoms are 
explained by known non-infectious reasons (15). However, this definition is not widely 
used in research without certain modifications, such as including additional symptoms 
among the criteria. The core element of the different definitions used in population-based 
studies or studies from general practice is the acute onset of enteric symptoms, most 
commonly loose stools or diarrhea (commonly defined as the passing of ≥ 3 loose stools 
in 24 hours) (3, 5-9, 11, 12, 14, 16). Additional symptoms often included in different 
gastroenteritis case definitions are nausea, abdominal pain, bloody stools, headache, 
fever, and joint pain.  
The severity of gastroenteritis ranges from asymptomatic or self-limiting symptoms to 





1.1.2 Epidemiology and microbiology 
Gastroenteritis has been a leading cause of morbidity and mortality through the history of 
mankind. Even the very foundation of epidemiology can be traced back to John Snow's 
work on identifying drinking water as source of the cholera epidemic in London in 1854 
(17, 18). Despite the progress of modern medicine, gastroenteritis is even today a leading 
cause of death in all ages globally, and the mortality among children under the age of 5 
years is particularly high (2).  
The burden of gastroenteritis is clearly highest in low-income countries, where many 
cases could have been prevented by improving access to safe water and health care, 
sanitation and childhood nutrition. In high-income countries gastroenteritis rarely causes 
death (3–5) but still causes significant socio-economic costs (6–9). Yet, while the 
mortality from most infectious diseases in the United States decreased from 1980 to 2014, 
there was an increase in mortality for diarrheal diseases which was the second leading 
cause of infectious diseases mortality in 2014 (1).  
Gastroenteritis can be caused by a number of different agents such as toxins (produced by 
bacteria such as Staphylococcus aureus, Clostridium perfringens and Bacillus cereus 
(19)), viruses (e.g. norovirus, rotavirus, adenovirus, enterovirus and astrovirus (20)), 
bacteria (e.g. Campylobacter spp., non-typhi salmonellae, Vibrio cholerae, Yersinia spp., 
Shigella spp. and pathogenic Escherichia coli (19)), and parasites (e.g. Giardia lamblia, 
Entamoeba histolytica and Cryptosporidium).  
Gastroenteritis can spread from person-to-person by fecal-oral transmission either by 
direct contact or indirectly by contaminated food, objects or surfaces. Specifically, 
norovirus can spread by direct or indirect contact with vomit from an infected person, 
even by ingesting small droplets of vomit spreading through the air (21, 22). 
Gastroenteritis cases are more likely to infect others when they have symptoms and 2-3 






During the last decade, polymerase chain reaction (PCR) diagnostics have become the 
primary method in routine microbiological investigation of stool samples from patients 
with gastroenteritis in Norway (23). This DNA-based method screens for a broad 
spectrum of viruses, bacteria and parasites (multiplex molecular panels) from one single 
rectal swab, with the results ready in just a few hours. Before PCR multiplex molecular 
panels were introduced, the primary investigation for gastrointestinal pathogens relied on 
a combination of different time consuming and labor-intensive methods such as culture, 
microscopy, and antigen detection (24). These methods also require that the clinician who 
requests the microbiological investigation selects the appropriate test for the suspected 
microbes.  
The shift to PCR diagnostics, in turn, affects the epidemiology of laboratory confirmed 
infections. Previously, stool samples from patients with suspected gastrointestinal 
infection were routinely tested for Salmonella, Campylobacter, Yersinia, Shigella and 
Vibrio, but testing for viruses, parasites and pathogenic E. coli was done only when 
clinically or epidemiologically indicated and thus considerably underreported (23). Even 
the criteria for notification to the Norwegian Surveillance System for Communicable 
Diseases (MSIS) have changed from a culture verified diagnosis to also include PCR 
positive cases for certain infections. This was introduced in 2017 for the notification of 
campylobacteriosis (23). Further, PCR diagnostics is highly sensitive and does not need a 
viable microorganism but only remnants of DNA from the microbe in the feces for the 
test to be positive. Consequently, the positivity rates of gastrointestinal pathogens 
increase by 2- to 4-fold compared to diagnostics by conventional methods (24). 
Thus, PCR diagnostics pose a risk of identifying microbes that are not of clinical or 
epidemiological importance. It is challenging for the clinicians to interpret the presence of 
organisms that have not been routinely tested for in the past (such as different viruses and 
enteroaggregative E. coli - EAEC) or decide whether microbes represent colonization or 





difficile). It is also worth noting that the microbiological laboratories in Norway use 
different multiplex molecular panels with various repertoires of microbes being tested for. 
Positive results from PCR diagnostics should be interpreted with caution until results 
from the more thorough follow-up investigation by conventional methods are ready, 
including antibiotic susceptibility testing when applicable.  
1.1.2.2 Stool samples: Who to be tested? 
All patients with gastroenteritis should not submit stool samples for testing, as it would be 
neither socio-economically appropriate nor necessary or desirable for adequate 
management of most patients with gastroenteritis. Stool samples should be submitted only 
when clinically or epidemiologically indicated and followed by clinical information to the 
microbiologists. There exist no clear-cut national guidelines for when to submit stool 
samples from gastroenteritis patients in primary care. However, a summary of 
recommendations from guidelines for antibiotic treatment and management of 
gastrointestinal infections is as follows (25, 26): Stool samples should be limited to 
patients where the results are expected to be either useful for choosing treatment, or for 
epidemiological or infection control reasons. In addition, stool samples should be 
submitted from patients with severe symptoms (bloody stools, fever, severe abdominal 
pain, frequent passing of loose stools, dehydration), comorbidities or compromised 
immune system, duration of symptoms more than one week or recent travel abroad. 
Decisions about testing impacts in turn the epidemiology of the different infections in the 
surveillance systems.  
The clinical features alone cannot be used to make certain inference about the causing 
organism. Still, the symptomatology can be of value to distinguish between suspected 
viral versus bacterial/protozoal cause: Symptoms of diarrhea but no vomiting, diarrhea 
lasting for more than 3 days, bloody diarrhea and fever are more common in bacterial or 
protozoal cause, whereas age < 5 years, onset in spring or winter and loss of appetite are 
more common in viral gastroenteritis (27, 28). Further, if known, information about 





symptoms) and time from exposure to symptom onset can contribute to suggest certain 
pathogens (28). The microbial cause can only be identified by microbiological 
investigation. However, a causing organism can be identified in less than 50% of stool 
samples from gastroenteritis patients presenting to primary care, and when identified it is 
most commonly viral (3, 11, 12, 14, 29).  
1.1.2.3 Seasonality 
Trends in seasonality are described for different microbes causing gastroenteritis (30-38), 
and the underlying mechanisms most probably vary for the different pathogens (34). The 
seasonality of common bacterial infections like salmonellosis and campylobacteriosis in 
Norway is distinct with peaking in August (36, 37), whereas the seasonality of common 
viral infections such as norovirus and rotavirus infection peak in December through 
February (30, 39) and March through May (32), respectively.  
Possible factors contributing to seasonality are holiday travels abroad, variability in 
temperature and humidity, start of school year, geographical localization on either 
Northern or Southern Hemisphere and level of country development (33-35). 
1.1.2.4 Viruses 
Viral gastroenteritis in Northern Europe is most commonly caused by norovirus or 
rotavirus (in unvaccinated young children) and is popularly called ‘stomach flu’ or 
‘winter vomiting disease’ as people have experience with their presence in the winter 
months, which is supported by the literature on seasonality (27, 30, 32, 39).  
Rotavirus infection has been the most common cause of severe gastroenteritis among 
children under the age of five in Norway (18, 19). After the rotavirus vaccine was 
included in Norway’s Childhood Immunization Program in 2014, a 45% decrease in 
gastroenteritis-associated hospitalizations among children < 5 years and reductions in 
gastroenteritis contacts in primary care have been demonstrated (40, 41).  
Norovirus is now the leading cause of gastroenteritis worldwide, and even emerged as the 





after implementation of rotavirus vaccination (20). Norovirus is highly infective and 
known to cause local outbreaks in institutions and in families with young children, and 
presents commonly as a self-limiting illness dominated by vomiting for 1-3 days (20, 28, 
42). Due to the genetic and antigenic diversity within norovirus, the development of a 
norovirus vaccine is challenging, although clinical trials for some vaccine candidates are 
ongoing (8). 
1.1.2.5 Bacteria and parasites 
The bacterial gastrointestinal infections are subject to notification to MSIS and updated 
compilations of surveillance data for these are available at the Norwegian Institute of 
Public Health’s (NIPH) online handbook on the prevention and control of infectious 
diseases (“Smittevernveilederen”) (22): Campylobacteriosis is the most common with 
2000-3000 cases annually, followed by salmonellosis (approx. 1000), E. coli enteritis 
(approx. 200-900), shigellosis (approx. 100) and yersiniosis (approx. 50-100). The 
parasitic infections giardiasis and cryptosporidiosis are notifiable in Norway, and in the 
recent years 300-500 cases of each have been reported annually. The majority of notified 
infections are acquired abroad. The proportion of domestically acquired infections differ, 
and is highest for yersiniosis (approx. 60%), enterohaemorrhagic E. coli enteritis (EHEC) 
(approx. 50%), campylobacteriosis and cryptosporidioisis (40-50%), giardiasis (20-30%), 
salmonellosis (approx. 20%). However, information on place of acquisition is missing for 
10-20%. 
Antibiotic-associated C. difficile infection has been notifiable to MSIS since 2012 (43) 
but is not readily considered gastroenteritis as it is an opportunistic and primarily 
nosocomial infection and a rare cause of diarrhea in the community (3).  
1.1.3 Use of health care services and management 
1.1.3.1 Use of primary health care services 
Most people with gastroenteritis in high-income countries experience self-limiting 





administrative reasons for the contact, such as need for sickness certification. Among 
those who seek health care services, most are managed in primary care. Of these, a small 
proportion is referred to hospital, and some submit stool samples for microbiological 
investigation. Consequently, the gastroenteritis cases with a laboratory verified pathogen, 
and thus subjects to being included in the surveillance statistics, represent only a fraction 
of cases in the health care services and in the population. These stages in reporting of 
cases with gastrointestinal infection to the surveillance system is often referred to as the 
‘notification pyramid’ (3).  
The incidence of self-reported gastroenteritis in the community varies between European 
countries. Although differences in methods and case definitions used make it difficult to 
compare the results of these studies directly, the incidence per person-year range from 
0.19 and 0,27 in the United Kingdom (3, 44), 0.28 and 0.45 in the Netherlands (12, 45), 
0.3 and 0.36 in Sweden (6, 7), 0.4 in Ireland (9), 0.9 in Poland (5), 1.2 Norway (16) and 
1.4 in Denmark (8).  
Studies from the United Kingdom and the Netherlands have identified the severity of 
illness and recent foreign travel to be the most important factors associated with 
gastroenteritis patients seeking their general practitioner (GP) (13, 46). Population-based 
studies from various European countries report that 0.9 - 30% of the gastroenteritis cases 
in the community contact the health care services (5-9, 13, 16, 45-47). In two Norwegian 
population studies from 1987 and 1999-2000, the proportion of gastroenteritis cases that 
consulted a doctor was 17% and 21%, respectively (16, 47). 
1.1.3.2 Management, treatment, and infection control measures 
Regardless the underlying pathogen, it is crucial in the treatment of gastroenteritis 
patients to ensure adequate compensation of fluid loss, and hospitalization for intravenous 
fluid therapy may be necessary. Symptoms like headache, joint- or muscle pain, or fever 





should be avoided in patients presenting to primary care with acute gastroenteritis, 
especially in children and cases with severe illness or bloody diarrhea (26, 48, 49).  
To reduce the risk of further spread, patients should be informed about simple, 
individualized infection control advice, such as thorough hand washing, good routines for 
toilet visits and cooking, as well as short-term isolation of the sick for at least 48 hours 
after symptom relief. Sick leave used as an infection control measure may be relevant to 
patients who due to their work pose an increased risk for further spread of the infection 
(food handling and patient contact) regardless of the patient’s clinical condition and 
functioning (50, 51). In Norway, updated details on general infection control advice and 
disease-specific control and follow-up regimens can be found at NIPH's website (52).  
1.1.4 Public health aspects of gastroenteritis 
1.1.4.1 Surveillance of gastrointestinal infections 
Surveillance of gastrointestinal infections in Norway is primarily based on laboratory-
confirmed cases, and the following gastrointestinal infections are subject to notification to 
MSIS (Communicable Diseases Notification System) when laboratory-confirmed: 
campylobacteriosis, enteropathogenic E. coli enteritis, salmonellosis, shigellosis, 
yersiniosis, cholera, giardiasis cryptosporidiosis and hemolytic-uremic syndrome (53, 54).  
An obvious disadvantage of a laboratory-based surveillance system is the delay from time 
of infection and symptom onset until a laboratory confirmed diagnosis is notified (55). 
Norwegian Syndrome Suveillance System (NorSySS) was introduced in Norway in 2017 
as a near real-time supplement to laboratory-based surveillance (56). The system is based 
on reimbursement claims data and shows the number of consultations in general practice 
and out-of-hours (OOH) services for the International Classification of Primary Care 
(ICPC) codes ‘D11 Diarrhea’, ‘D70 Intestinal infection’ and ‘D73 Gastroenteritis 
suspected infectious’ over a given period. The diagnoses are primarily based on the 






Gastroenteritis of any microbiological cause can appear as outbreaks. An outbreak can be 
defined as “two or more cases of a disease that is suspected to have a common source, or 
a number of cases that clearly exceed what one would expect (i.e. the endemic level - the 
normal background level of the disease) within an area in a given period of time” (57).  
According to Norwegian regulations (MSIS-forskriften) and the International Health 
Regulations (IHR), all physicians in Norway have a duty to immediately send an early 
warning notification to the municipal public health officer if an outbreak of infectious 
disease is suspected, even when there is no laboratory-verified diagnosis (58). Early 
warnings of outbreaks related to food or drinking water are highlighted as of particular 
importance. Additionally, early warning notification also applies to isolated cases (one 
patient only) of cholera, diarrhea-associated hemolytic uremic syndrome (HUS) and 
enterohemorrhagic E. coli (EHEC) infection (58).  
1.1.4.3 Public health and veterinary medicine 
Many of the infections causing gastroenteritis are zoonoses (transmission between 
animals and humans) and foodborne diseases. Thus, public health and veterinary 
authorities are collaborating closely in the surveillance of foodborne illness and 
pathogens, both at a local (municipal public health officer and local Food Safety 
Authority), national (NIPH and Norwegian Food Safety Authority and Veterinary 
Institute) and a European level (European Centre for Disease Prevention and Control 
(ECDC) and European Food Safety Authority (EFSA)). 
1.2 Campylobacter infections 
A more detailed description of Campylobacter infections follows, as one part of this 
thesis (Paper III) is about a large waterborne Campylobacter outbreak that took place on 






Campylobacter spp. are small, curved or spiral shaped Gram-negative bacilli (59). There 
are many species of Campylobacter, but C. coli and C. jejuni are causing most infections 
in humans, of which C. jejuni is the most common (59, 60). As of 2018, approx. 50% of 
all notified Campylobacter cases are PCR diagnosed only, without culture verification 
(23).  
1.2.2 Epidemiology and outbreaks 
Campylobacter was recognized as a human pathogen in the 1970s (59, 61), and is now the 
most common bacterial cause of gastroenteritis worldwide (62), in Europe (63), and in 
Norway (60). Annually, approx. 3000 cases in Norway are reported to MSIS of which 
more than 50% are infected abroad. The annual incidence of non-foreign travel related 
Campylobacter infections in Norway is estimated to 28.5 cases/100 000 during the years 
2000-2014, but increasing after 2004, a trend also observed in Sweden, Finland (36) and 
the United States (64). The most common risk factors for domestically acquired 
Campylobacter infection in Norway are drinking untreated water, eating poultry, or eating 
and preparing barbeque meals (65, 66). Several waterborne outbreaks from Norway or 
other Nordic countries have been described (67-70).  
The Campylobacter bacteria are found in Norwegian wildlife, most commonly in the guts 
of wild birds but can also be found in cattle, dogs and cats (60). As of 2019, the 
prevalence of Campylobacter in broiler flocks in Norway were 5.1%, which is low 
compared to other countries (60). 
1.2.3 Clinical features 
The clinical features of gastroenteritis caused by Campylobacter spp. are not different 
from other bacterial gastroenteritis. The most common symptoms include diarrhea (≥ 3 
loose stools in 24 hours), nausea, vomiting, abdominal pain, and bloody stools (59, 61, 





to affect colon, but in some the infection starts with symptoms of acute colitis such as 
frequent passing of watery stools or bloody diarrhea (71).  
The illness is usually mild and self-limiting, but some experience severe illness with 
systemic illness or long-lasting frequent diarrhea leading to need for hospital care, or even 
lethal disease (59, 61, 71-77). Bloody stools and fever are considered markers of more 
severe infections (71, 76, 78, 79).  
Campylobacter infection is known to have the ability to cause post-infectious 
complications such as the Guillain-Barré syndrome (acute immune-mediated 
polynevropathy), reactive arthritis, and irritable syndrome (IBS) (59, 80-84).  
The studies comprising the literature on symptoms and clinical features of 
campylobacteriosis were predominantly published from 1970s to 2000 and are mostly 
based on either surveillance data or laboratory verified sporadic cases of infection (59, 61, 
72-75, 78, 79). Such cases represent a selected group that may differ from the total 
symptomatic cases in the community (3, 44).  
In the literature of epidemiological studies on Campylobacter infection, most are outbreak 
investigation studies with the aim to identify the source and the size of the outbreak. 
Outbreaks often happen without warning and there will always be some delay before it is 
acknowledged. It is difficult to plan research in advance and also to launch the study in 
the acute phase when focus is on managing the outbreak and its consequences. Hence, 
both comprehensive baseline data and data on symptoms and clinical features from 
outbreaks are relatively rare. 
The description of antibiotic treatment of Campylobacter infections can be found in the 
following section ‘1.3.3 Antibiotic treatment of Campylobacter’. 
1.3 Antibiotic treatment of gastrointestinal infections 
Since antibiotics were commercialized in the years following World War II, antibiotic 





infectious diseases. However, antibiotics are less important for the treatment of 
gastroenteritis, and Norwegian guidelines and international recommendations state that 
antibiotics should be avoided for the treatment of gastroenteritis in primary care (25, 26). 
Norway generally has a low consumption of antibiotics compared to most other European 
countries (85). In high-income countries, gastroenteritis is rarely treated with antibiotics 
in primary care, with prescribing proportions ranging from 5 to 11% varying between 
countries (86-88). In contrast, a study from low- and middle-income countries found that 
approx. 50% of children under the age of 5 years with diarrhea who visited a health-care 
facility were treated with antibiotics (89). 
1.3.1 Empiric antibiotic treatment 
Empirical treatment with antibiotics (treatment without a verified microbe) seems 
particularly inappropriate in Norway as studies of gastroenteritis cases in primary care in 
countries from Northern Europe have shown that the infective agents are most commonly 
either viruses or cannot be identified (3, 11, 12, 29). Even in travel related gastroenteritis 
without a verified microbe, often referred to as ‘tourist diarrhea’, empiric antibiotic 
treatment should be avoided in primary care. This also applies to infections imported from 
parts of the world where bacterial and parasitic gastrointestinal pathogens are more 
prevalent, as imported infections more often are caused by antibiotic resistant microbes. 
Instead, patients with tourist diarrhea that present to primary care should be tested, and 
antibiotic treatment not considered before the results of the susceptibility tests are 
available. If the clinical condition requires urgent treatment, the patient should be 
hospitalized.  
1.3.2 Specific antibiotic treatment 
For most causal microbes, antibiotics are not shown to shorten the symptomatic phase of 
gastroenteritis, and in some cases could contribute to a more serious outcome in infections 
caused by E. coli and Salmonella (90, 91). However, specific antibiotic treatment is 





as shigellosis, giardiasis and amoebiasis, although primarily in the hospital setting (25, 
92).  
Antibiotics approved for per oral treatment (thus can be used in the primary care setting) 
of specific gastrointestinal infections in Norway are macrolides, fluoroquinolones, 
tetracyclines, trimethoprim-sulphamethoxazole and vancomycin (25, 92).  
1.3.3 Antibiotic treatment of Campylobacter 
Antibiotics are usually not needed in treatment of campylobacteriosis but may be useful 
in the hospital setting in patients with severe illness or risk of severe illness (25, 71, 78, 
79, 92-94). When antibiotic treatment of Campylobacter infection is indicated, macrolides 
(erythromycin or azithromycin) are the antibiotics of choice (71, 92, 93). There is an 
increase in fluoroquinolone resistance in Campylobacter species in many parts of the 
world, and macrolide resistance has also been reported in some countries although to 
lesser extent (71, 93).  
1.3.4 Antimicrobial resistance 
Antimicrobial resistance (AMR) is a major challenge to global public health (95). The 
ECDC has estimated that 33 000 patients died as a direct consequence of infections with 
antibiotic-resistant bacteria in the European Union (EU) and the European Economic 
Area in 2015 (96). As of today, the situation regarding resistant microbes in humans and 
animals in Norway is favorable (97). However, resistant microbes in zoonoses and 
foodborne illnesses are increasing in the EU (98), and fluoroquinolone-resistant 
Campylobacter spp., Salmonella spp., and Shigella spp. are on the WHO priority list of 
antibiotic-resistant bacteria (99).  
One of the drivers of AMR is the antibiotic use itself through the process of selective 
pressure (100). In 2015, the Norwegian Government’s Action Plan to Fight Antimicrobial 
Resistance in the Health Care Services (the Action Plan) launched a goal to reduce the 





the level of prescriptions in 2012 (101). Measures to reduce inappropriate use of 






2. Aims of present study 
This thesis is comprised by sub-studies of two research projects: 
A) Antibiotic use in Primary Care in Norway (APRINOR), a registry-based project 
investigating the epidemiology and antibiotic treatment of infections in general 
practice and out-of-hours services in Norway.  
B) Askøy Campylobacter Outbreak Study (ASCOS), a longitudinal cohort study 
following a large waterborne campylobacter outbreak in Askøy, Norway in June 
2019. 
 
The aims of the studies comprising this thesis were: 
Paper I: To investigate the extent of, and explore characteristics associated with, 
consultations for gastroenteritis in primary care and to compare consultations in daytime 
general practice and out-of-hours services in Norway.  
Paper II: To investigate time trends and patient characteristics associated with antibiotic 
treatment for gastroenteritis in Norwegian primary care in a 10-year period.  
Paper III: To describe the clinical features of self-reported gastroenteritis in the 







3. Materials and methods 
3.1 Paper I and II 
Paper I and Paper II are presented together because the same design and data material 
were used for both. Paper I was a registry-based cohort study using reimbursement claims 
data, and in Paper II these data were linked to prescription data.  
3.1.1 Setting and design 
3.1.1.1 Norwegian primary care 
As part of the national public health care system in Norway, all residents are entitled to 
sign up with a specific GP. As of 2015, 99% of the population was registered to this 
service (102). If medical care is needed either for acute or chronic illness, patients are 
supposed to contact their GP. Further, the GP has responsibility for long-term care for the 
patients on their list. Most consultations in primary care in Norway are carried out in the 
general practice opening hours, including daytime emergency consultations. Additionally, 
emergency medical services are organized as out-of-hours (OOH) services either with 
general practitioners on duty in the municipalities, or as 24-hour emergency services in 
some of the larger cities.  
The traditional consultation by the patient’s physical encounter with a doctor in the 
surgery represent a clinical situation enabling a proper examination and adequate 
treatment. This was the most common form of consultation in primary care, during the 
study period 2006-15 although video and e-consultations have become more common in 
recent years, especially during the ongoing SARS-CoV-2 pandemic. As opposed to 
consultations, ‘simple contacts’ are not face to face encounters but include telephone 
contacts and advice, and administrative requests for such as sickness certificates or 
prescribing of regular medication. GPs in Norway do home visits, but to a small extent 
and primarily for preventive purposes and follow up of frail and elderly patients with co-
morbidity. In the OOH services, home visits constituted 3.2% of the consultations in 2015 





services outside the national public health care services were not common in Norway in 
the study period 2006-15. 
3.1.1.2 International Classification of Primary Care (ICPC) 
Each contact in primary care is coded according to ICPC. The ICPC coding system was 
first published in 1987 by World Organization of Family Doctors (WONCA) (104), and is 
accepted by the World Health Organization (WHO) as a reason for encounter 
classification for primary care or general practice (105). Since 1992, Norwegian primary 
care doctors are required to use at least one ICPC-2 code on reimbursement claims (104). 
Each ICPC code consist of one letter indicating organ chapter (‘D – Digestive’ etc.), and 
two digits where 00-29 indicate symptom diagnoses and 70-99 indicate disease diagnoses 
(106). The first two codes in the electronic medical records are automatically copied to 
the reimbursement claim for each contact. 
3.1.1.3 Sickness certificates 
Doctors in primary care play a key role in certifying sickness absence. Most employees 
need documentation from a physician for sick leave exceeding three days. Sickness 
certification are also used for infection control purposes in certain settings. As the GPs are 
responsible for long-term follow-up of the patients on their lists, GPs are particularly 
involved in the certification and follow-up of sick leave in Norway.  
3.1.1.4 Point-of-care C-reactive protein tests 
Point-of-care C-reactive protein (CRP) testing is a reimbursed procedure that is widely 
used in general practice and OOH services in Norway, and the use is particularly high in 
consultations where an infection is suspected and in the OOH services (107, 108).  
3.1.1.5 Prescription of antibiotics 
Antibiotics are subject to prescription in Norway, and more than 80% of all antibiotics are 
prescribed in primary care. Respiratory tract infections is the main reason for prescribing, 
and narrow spectrum antibiotics are most common (97). When a physician finds treatment 





antibiotics dispensed from a pharmacy. Information about the indication for treatment 
(diagnosis or type of infection) is not included in the prescriptions for antibiotics. 
3.1.2 Source of data 
3.1.2.1 Reimbursement claims database (KUHR) 
It is mandatory for doctors in general practice and OOH services to send electronically 
reimbursement claims for all contacts to the Norwegian Health Economics Administration 
(HELFO) at least every 14 days. 
For each contact, the reimbursement claims include information about the patient (unique 
personal identifier, age, and sex), type of service (daytime general practice or OOH 
services), date, and diagnoses (ICPC-2 codes). In addition, the reimbursement claims 
contain information about reimbursed procedures such as point-of-care CRP testing and 
issuing of sickness certificates, but there exist no codes that specifically indicate 
microbiological testing of stool samples.  
Data from these reimbursement claims are consecutively collected in the KUHR (Control 
and Payment of Health Reimbursements) database, primarily for administrative purposes 
although widely used for research on primary care activity. The KUHR database was not 
defined as a national health register during the study period but was later incorporated as 
a central part of the Norwegian Register of Primary Care (KPR) that was established as a 
mandatory national health register in 2017.  
In Paper I and Paper II, we used KUHR data from all consultations by attendance in 
general practice and OOH services for the period 2006-15. Data from consultations made 
by telephone or electronically, and home visits were not included in the data set extracted 
from KUHR. For administrative reasons, daytime activity data from the 24-hour 
emergency services in Bergen (the second largest city in the country with 5% of the total 






3.1.2.2 Norwegian Prescription Database (NorPD) 
NorPD is a registry of all prescription drugs dispensed from pharmacies and one of the 
mandatory national health registries in Norway. NorPD was established in 2004 and the 
data are complete and comparable for the years after 2005. Drugs used for treatment of 
inpatients in hospitals and nursing homes are not registered in NorPD as they are not 
dispensed from pharmacies.  
For each dispensation, NorPD contains information about the patient (pseudonym 
personal identifier, age, sex), time for the dispensation, and information about the drug 
(Anatomical Therapeutic Chemical (ATC) classification system).  
In Paper II, we used data from the NorPD for all prescribed systemic antibiotic courses 
dispensed from pharmacies in Norway during the 10-year period, 2006-15.  
3.1.2.3 Linking of data sets 
In Paper II, the data from NorPD was linked to the KUHR data set by the patients’ 
pseudonym unique personal identifier and proximity in time for the registered events in 
the two data sets.  
3.1.3 Definitions of variables 
3.1.3.1 Variables used in both Paper I and Paper II 
Focusing on clinical cases being eligible to further examination and treatment, a 
‘consultation’ was defined as a patient’s physical encounter with a doctor. Consultations 
made electronically, by home visits or telephone were not included in this study.  
A ‘gastroenteritis consultation’ was defined as a consultation with one or more of the 
following ICPC codes: ‘D11 Diarrhea’, ‘D70 Gastrointestinal infection’ and ‘D73 
Gastroenteritis, presumed infection’. These ICPC codes are defining gastroenteritis in 
NorSYSS (109). D11 is a symptom diagnosis and the least specific of the three, whereas 





gastrointestinal infection, and D70 include symptomatic cases of all specified 
gastrointestinal infections.  
‘Type of service’ was predefined by the registry, and we categorized this variable into 
‘general practice’ and ‘OOH service’.  
Patient sex was predefined in the registry. Patient age was categorized into the following 
ten categories: 0-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84 and ≥ 85 years. 
Analyses for the issuing of sickness certificates were restricted to patients aged 20-67 
years only.  
3.1.3.2 Time variables 
The reimbursement claims data were extracted from KUHR at two different occasions: 1) 
delivered directly to us for the use in Paper I and 2) delivered via NIPH to be prepared for 
the purpose of linking to the NorPD. Due to privacy concerns, the Norwegian Data 
Protection Authority would not accept original dates coupled with patient data. These 
were therefore replaced by Statistics Norway with a random reference date unique for 
each patient, from which the time of each registration in this dataset refers to. However, 
year and quarter of a year were accepted as the most detailed level of the time variable. 
Quarter refers to time period of year for the consultations as follows: January-March, 
April-June, July-September and October-December. We further categorised time period 
into summer (combining April-June and July-September quarters) and winter seasons 
(combining October-December and January-March quarters).  
Due to an error, the variable ‘quarter’ was not included in the data set extracted from 
KUHR to be linked to the NorPD. Consequently, year is the most detailed level of time in 
Paper II, in addition to the chronological variable ‘reference date’.  
3.1.3.3 Antibiotics related variables (Paper II only) 
A ‘course of antibiotics’ was defined as a course of a prescribed systemic antimicrobial 
drug dispensed from a pharmacy and registered in the NorPD with the following ATC 





Metronidazole”. We further dichotomized the antibiotics due to their relevance in 
treatment of gastrointestinal infections according to Norwegian and international 
guidelines: ‘gastroenteritis relevant’ included fluoroquinolones, metronidazole, 
macrolides, tetracycline, trimethoprim-sulphamethoxazole and vancomycin, whereas all 
other antibiotics were defined as ‘not gastroenteritis relevant’.  
Antibiotics that have urinary tract infection (UTI) as the only indication were defined as 
‘UTI antibiotics’ (pivmecillinam, mecillinam, trimethoprim, nitrofurantoin and 
metenamin). 
The consultation data from the KUHR database were linked to the drug prescription data 
from NorPD by the patients’ pseudonym unique personal identifiers and the reference 
date variable. We extracted for further analyses all gastroenteritis consultations, and 
considered a course of antibiotics that was dispensed from the pharmacy at the same day 
or the day after one of these consultations as linked to that gastroenteritis consultation.  
Hence, antibiotics defined as ‘gastroenteritis relevant’ or ‘not gastroenteritis relevant’ 
were included as treatment for gastroenteritis in the analyses, provided they were 
dispensed as described above. The exceptions were the following two categories: 1) 
Courses of antibiotics (both ‘gastroenteritis relevant’ and ‘not gastroenteritis relevant’) 
linked to consultations with a co-diagnosis (other than D11, D70 or D73) likely to explain 
the prescription (see Supplementary Table S1 in Paper II), and 2) courses of ‘UTI 
antibiotics.’ These courses were excluded as treatment for gastroenteritis, and 
consultations linked to such courses were included as gastroenteritis consultations without 
antibiotic treatment for gastroenteritis in the analyses (see Figure 1 in Paper II).  
3.1.4 Statistical methods 
Descriptive statistics were calculated as the percentage of gastroenteritis consultations out 
of the total number of consultations for any diagnosis in Paper I, and as the percentage of 





Patient characteristics, use of CRP and issuing of sickness certificates were compared 
between gastroenteritis consultations and consultations for any diagnosis, between 
gastroenteritis consultations with and without antibiotic treatment, and between 
gastroenteritis consultations in general practice and in OOH services. We explored time 
trends in consultations, use of CRP testing, and the use of different antibiotics as 
treatment for gastroenteritis. Possible associations with patient age and sex, time of year 
for the consultations (Paper I only), use of point-of-care CRP testing and sickness 
certificate issuing in the consultations were investigated by bivariate statistics.  
The high numbers of observations in the data material made even small differences and 
associations significant at the <0.05 significance level.  
The data were analyzed using Stata/MP 15.0 and Microsoft Excel 2010 for Windows in 
Paper I, and StataSE 16.1 and Microsoft Excel for Windows 365 MSO in Paper II, for 
frequency and bivariate analyses. All data have been stored, processed, and analyzed on 
the University of Bergen’s solution for secure processing of sensitive personal data in 
research (SAFE). 
3.1.5 Ethical approval 
Paper I and II were approved by Regional Committee for Medical and Health Research 
Ethics REC West (project number 2016/559) and The Norwegian Data Protection Agency 
(project number 16/01083). 
3.2 Paper III 
Paper III was a population-based cohort study using data collected using an online 
questionnaire during a large waterborne Campylobacter outbreak. 
3.2.1 Setting and design 
On 6 June 2019, an outbreak of gastroenteritis was detected on the island municipality 
Askøy, which has approx. 29 500 inhabitants. More than 1 500 inhabitants reported 





had been contaminated by Campylobacer jejuni at some time in late May 2019 (110). 
Two deaths were related to the outbreak and 67 patients were admitted to hospital (110, 
111). We established a large population-based cohort study and started to invite 
participants by text message (SMS) and collect data using a web-based questionnaire 14 
days after the outbreak was acknowledged. Ethical approval was obtained before the 
invitations were sent out.   
3.2.2 Participants 
Text message was sent by the municipality of Askøy to approx. 1 600 mobile phones in 
Askøy on 20 June 2019, using the municipality’s warning system. The text message 
encouraged all household members to answer the survey. Participants of all ages were 
included in the study. Inclusion was closed on 1 July 2019.   
Participants were asked if they were ill during the outbreak, and participants who 
responded ‘yes’ were further asked about the symptoms, whereas those answering ‘no’ or 
‘uncertain’ about acute illness did not receive these questions. The study population 
includes all participants who were ill during the outbreak, excluding those who had not 
been in Askøy at the time of the outbreak. 
A ‘case’ was defined as a participant who reported being ill with gastrointestinal 
symptoms during the outbreak, with symptom onset in the study period, and who 
experienced at least one of the following symptoms (see Figure 1 in Paper III): loose 
stools, diarrhea, bloody stools, abdominal pain, vomiting and nausea. A ‘non-case’ was 
defined as a participant reporting not being ill during the outbreak or who reported being 
ill but did not fulfil the symptom criteria. An ‘uncertain’ was defined as a participant who 
was uncertain whether being ill during the outbreak or reported being ill and fulfilling the 
symptom criteria but with symptom onset either before the study period or missing. 
3.2.3 The questionnaire 
Paper III is based on data from the baseline survey out of totally four surveys in the 





the outbreak. The content of the questionnaire was based on existing literature and chosen 
to both describe the ongoing outbreak and to serve as baseline for topics in the follow-up 
surveys.  
A paper version of the web-based questionnaire can be found in Appendix. In addition to 
status regarding illness and whereabouts during the outbreak (accounted for under the 
above section ‘3.3.2 Participants’), the following topics from the questionnaire were 
relevant to Paper III: the acute disease (symptoms, duration of each symptom, duration of 
disease and perceived severity), management (use of health care services and medication) 
and consequences of the disease (absence from work or school), age, sex, educational 
level, employment situation, marital status, household total income, self-reported previous 
diseases, intake of glasses with tap water during the week prior to outbreak, intake of 
alcohol units during a normal week and tobacco use.  
3.2.4 Variables 
We defined the outcome ‘severe gastroenteritis’ as cases reporting diarrhea for ≥ 5 days 
and at least one of either fever for ≥ 2 days or bloody stools. This outcome variable was 
based on existing literature (71, 76, 78, 79), as well as clinical experiences and expertise 
among members in the research group and aimed to capture a set of symptoms which 
indicated a greater extent of both local inflammation in the bowels and more generalized 
disease. Thus, the ‘severe gastroenteritis’ outcome was defined independently of the 
variable ‘perceived severity’ which covered self-assessed perceived severity at the worst 
time point during the acute illness. 
We defined two different categorical variables for age, with three (0-24, 25-54 and ≥ 55 
years) and 10 categories (0-4, 5-14, 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84 and 
≥ 85 years), respectively. We categorized duration of illness into 0-3, 4-7, 8-14 and ≥ 15 
days. Tobacco use was dichotomized, and alcohol units were categorized into the 
following six categories: 0, 1-2, 3-5, 6-9, 10-14 and ≥ 15 units per week. For the analyses 





educational level, employment situation and marital status, were restricted to participants 
≥ 18 years.  
There was a high proportion of missing data for the variables age and sex in the baseline 
survey (29% and 26% respectively). However, we were able to add data from the follow-
up surveys for 580 and 507 participants, respectively. Thus, in the final study population 
there were 13% missing age and 12% missing sex information. 
3.2.5 Analyses and statistical methods 
Differences between proportions in cross tables were tested with Pearson’s x2-test for 
associations. For the outcome severe vs non-severe gastroenteritis, we estimated relative 
risks (RR) using a modified Poisson regression model (112) since this was a cohort design 
with a common outcome (23.7%). Confounding was investigated, and adjusted for when 
appropriate, in the regression models. Level of statistical significance was set at p<0.05. 
We used the online questionniare tool SurveyXact by Rambøll. The software R, StataSE 
16.1 and Microsoft Excel for Windows 365 MSO were used for processing and analyzing 
the data. All data have been stored, processed, and analyzed on the University of Bergen’s 
solution for secure processing of sensitive personal data in research (SAFE). 
3.2.6 Ethical approvals 
Paper III was approved by Regional Committee for Medical and Health Research Ethics 
REC West (project number 2019/1086). Consent from parents was needed for participants 






4.1 Paper I 
Over the period 2006-15, there were 1 281 048 gastroenteritis consultations in Norwegian 
primary care of which 84.4% (n=1 081 774) were in general practice and 15.6 % 
(n=199 274) in the OOH services. This constituted 0.9% of all consultations for any 
diagnosis in primary care, and 0.5% and 1.6% of consultations in general practice and the 
OOH services, respectively.  
The patients in the gastroenteritis consultations were dominated by young children aged 
0-4 years (n=272 460, 21.3%) and young adults aged 25-34 years (n=210 226, 16.4%), 
which was also observed in both general practice and the OOH services. 
Mean annual number of gastroenteritis consultations was 128 104. There was an overall 
10.3% increase in number of gastroenteritis consultations from 120 624 in 2006, to 
133 091 consultations in 2015. Due to an even higher increase in consultations for any 
diagnosis over the same period (25.3% increase), the proportion of gastroenteritis 
consultations decreased slightly from 1% in 2006 to 0.9% in 2015. The population of 
Norway increased by 11.3% from 2006 (n=4 640 219) to 2015 (n=5 165 802) (113). 
We observed a bi-annual cycle of both the number and proportion of gastroenteritis 
consultations through the whole period, a pattern of variation most pronounced for the age 
category 0-4 years in both service types. After organizing the data according to winter and 
summer seasons, as the shift of the year split each winter season, these analyses did not 
show a similar bi-annual cycle from one winter season to the next.  
We observed variations in gastroenteritis consultations frequencies peaking during 
January-March (29.3 %) followed by October-December (25.0 %), both in general 
practice and OOH services. This seasonal variation was most evident for the age 





gastroenteritis consultations in both service types were more equally distributed through 
the quarters.   
Point-of-care CRP testing was used in 36.1% of the gastroenteritis consultations, 32.2% 
of the consultations in general practice and 57.4% in the OOH services.   
Among patients in the working age (age group 20-67 years), sickness certificates were 
issued in 43.6% of the gastroenteritis consultations; 45.9 % in general practice and 24.6 % 
in OOH services.  
4.2 Paper II 
A course of systemic antibiotics was dispensed from the pharmacies within 1 day after 30 
5054 of totally 1 279 867 gastroenteritis consultations in Norway in the period 2006-15. 
As mentioned in the methods section, we did not include the following linked antibiotic 
courses as treatment of gastroenteritis (see Figure 1 in Paper II): 1) gastroenteritis 
consultations with a co-diagnosis more relevant to the prescription (n=3 956) of which 
2 076 were an R-diagnosis in ICPC-2, indicating a respiratory tract infection, and 1) 
gastroenteritis consultations linked to courses of UTI antibiotics (n=2 926). Consequently, 
there were a total of 23 663 gastroenteritis consultations with antibiotic treatment which 
constitutes a 1.8% antibiotic treatment proportion. In general practice the antibiotic 
treatment proportion of gastroenteritis consultations was 1.8% (n=19 617), and 2.0% 
(n=4 046) in the OOH services.  
We observed an increase in the antibiotic treatment proportion of the gastroenteritis 
consultations from 1.4% in 2006 to 2.2% in 2012, then decreasing to 1.8% in 2015. A 
similar pattern was observed for the absolute number of gastroenteritis consultations with 
antibiotic treatment.  
The lowest proportion of antibiotic treatment was observed in gastroenteritis consultations 
with the youngest children aged 0-4 years (1.0%), then increasing with increasing age up 





the two age categories 55-64 and 65-74 years. This trend was even more pronounced in 
the OOH-services, with a peak antibiotic treatment proportion of 4.6% in gastroenteritis 
consultations with patients aged 55-64 years.  
CRP testing was used in 58.1% of the gastroenteritis consultations with antibiotic 
treatment, as compared to 35.7% without antibiotic treatment, and was more frequently 
used in OOH services than in general practice in both gastroenteritis consultations with 
(OOH services 72.4% vs. general practice 55.1%) and without (OOH services 57.1% vs. 
general practice 31.7%) antibiotic treatment.  
We observed an increase in proportion of CRP testing in gastroenteritis consultations 
from 2006 (52.4%) to 2012 (60.8%), but then remained stable at approx. 61% until 2015.  
The 23 663 gastroenteritis consultations with antibiotic treatment were linked to 25 956 
antibiotic courses, as 90.3% (n=21 378) were linked to single courses, 9.6% (n=2 277) to 
two courses, and 0.03% (n=8) to three antibiotic courses. 
Of these 25 956 antibiotic courses, the most frequently used were fluoroquinolones 
(28.9%), metronidazole (26.8%), beta-lactamase sensitive penicillins (10.8%) and 
macrolides (10.4%), although beta-lactamase sensitive penicillins were defined as ‘not 
gastroenteritis relevant.’ 
From 2006-12, there was an increase in the number of courses of the ‘gastroenteritis 
relevant’ fluoroquinolones (128% increase), metronidazole (92.1% increase), 
sulfamethoxazole/trimethoprim (68.6% increase), tetracyclines (50.7% increase) and 
macrolides (64% increase). From 2012-15 there was a decrease in number of courses of 
all these antibiotics, except for metronidazole which continued a slight increase. 
The most frequent combination among the 2 277 double courses was metronidazole and 
fluoroquinolones (38.1%, n=868), followed by metronidazole and extended spectrum 
penicillins (27.3%, n=621), metronidazole and tetracyclins (15.8%, n=359), and 





4.3 Paper III 
Of the 8681 individuals who accessed the web site with the questionnaire, 3885 answered 
the questionnaire (see Figure 1 in Paper III). Two-hundred-and-sixty-one participants who 
either stated they had stayed outside Askøy (n=209) or with missing information whether 
they had been ill during the outbreak (n=52) were excluded, leaving a study population of 
3624 participants. Of these, 749 (20.7%) were cases, 2417 (66.7%) non-cases and 458 
(12.6%) were uncertain.  
The most frequently reported symptoms were tiredness (91.2%), loose stools (90.7%), 
abdominal pain (89.3%) and diarrhea (88.9%). Bloody stools (14.2%) was the least 
frequently reported symptom, and were most common in cases aged 0-25 years (25.6%) 
although none of these were under the age of 15 years. Joint pain was reported by 50.2%.  
The duration of illness ranged from 0 to 24 days (median = 6 days). For treatment of the 
acute illness, paracetamol (62.8%) followed by non-steroidal anti-inflammatory drugs 
(NSAIDs) (31.8%) were the most commonly used medication. Twenty-one cases (n=21) 
had been treated with antibiotics, but none of these cases were under the age of 15 years. 
Antibiotic treatment was more common among hospitalized patients (30.3%, n=10) than 
those not hospitalized (1.5%, n=11). 
Twenty-seven per cent (n=203) of the cases reported to have consulted a primary care 
doctor, and 4.2% (n=33) had been admitted to hospital. None of the hospitalized cases in 
the survey were under the age of 15 years.  
Twenty-four per cent of the cases (n=177) fulfilled the definition of ‘severe 
gastroenteritis’. Cases with severe gastroenteritis more often reported drinking > 5 glasses 
of tap water (41.2% vs 30.4%, p=0.02), previous gastric ulcer disease (13.6% vs 2.3%, 
p=0.01) and previous depression (16.9% vs 10.3%, p=0.02), compared to cases with non-
severe gastroenteritis. In the adjusted modified Poisson regression analyses, previous 
depression (RR: 1.61, 95% CI 1.16-2.24) and previous peptic ulcer disease (RR: 1.73, 





gastroenteritis. Further, age 55-64 years (RR: 0.62, 95% CI 0.41-2.46) and 35-44 (RR: 
0.52, 95% CI 0.35-0.77), were associated with a lowered risk of severe gastroenteritis as 
compared to the reference age category 45-54 years, although the RR for age 55-64 years 






5.1 Scientific theoretical considerations 
The core of this thesis is ‘gastroenteritis’, which is a generic term that encompasses a 
variety of different infections and conditions. The variety in use of different generic terms 
(gastroenteritis, acute diarrhea, infectious diarrhea, infectious intestinal disease etc.) and 
in methodological approaches by infection specific studies (population-based, notified 
sporadic cases, outbreak investigation studies etc.) have made the comparison of our 
results with relevant background literature challenging. 
Gastroenteritis occurs frequently in the population, and most of us have experienced at 
least one episode in our life. Thus, there is a common sense, both in the community and 
among health care professionals and researchers, of what gastroenteritis is, although not 
necessarily referring to the term. Consequently, it can be challenging to choose the best 
scientific documentation to refer to when it comes to matters that are largely common 
sense. 
From a scientific theoretical point of view, it is interesting to note that most of the 
literature on clinical features of Campylobacter infections was published in the 1970s and 
through the 1980s, shortly after the bacteria was acknowledged as a pathogen to humans. 
These descriptions of clinical features define what is considered typical for 
Campylobacter infections, which in turn affects whether the clinicians’ suspect the 
infection and thus becomes important for management when it comes to testing, 
notification, and treatment. A self-reinforcing process arises where you may find what 
you are looking for.  
5.2 Methodological considerations 
5.2.1 Paper I and Paper II 
The main strength of these two registry-based cohort studies is the use of complete 





courses of systemic antibiotics dispensed from pharmacies in Norway during a ten-year 
period from 2006-15. This reduces selection bias considerably. The use of comparable 
data for a 10-year period provides a unique opportunity to study trends in contact patterns 
in primary care and use of antibiotics for gastroenteritis.  
5.2.1.1 Two different data sets extracted from KUHR 
The reimbursement claims data were extracted from KUHR at to different occasions, and 
this had some consequences. First, there is a discrepancy of 1 181 in total number of 
gastroenteritis consultations in the two data sets. We assume that the difference is either 
by corrections or adjustments in the KUHR data base between the two extractions, a 
result of randomly different outcomes of data management and processing (such as 
handling of duplicates), or a combination of the two. The discrepancy is relatively small 
(0.09%) and we could not identify any systematic differences or deviations between the 
two data sets. Second, the variable ‘quarter of a year’ was not included in the data set that 
was linked to the NorPD data. Consequently, we could not look at possible seasonal 
variation in prescribing. 
5.2.1.2 Consultations in primary care 
A part of the reimbursement claims from the 24-hour emergency services in Bergen 
(daytime consultations from workdays) are not included, leading to a minor 
underreporting of consultations in the OOH services. This study was designed to 
investigate the face-to-face consultation activity concerning gastroenteritis, focusing on 
clinical cases being eligible to further examination and treatment. Thus, claims from 
electronic/telephone consultations or home visits were not included in the current study. 
We expect that the use of telephone consultations is considerable, due to the nature of 
gastroenteritis as a contagious disease. But these are probably dominated by requests for 
sick leave or similar administrative purposes, and also more prone to misclassification of 
disease on reimbursement claims (114). The lack of telephone consultations and home 
visits may challenge the external validity specifically in the context of syndromic 





telephone contacts may be used in the follow up of patients, and if these contacts result in 
the prescription of antibiotics these courses would be missing in our study.  
5.2.1.3 Precision of the time variable 
Another limitation is the lack of precision in the time variable. For the analyses of 
seasonality in Paper I, we should ideally have had information about the exact date or 
week number for the consultations.   
5.2.1.4 Classification of disease 
Possible misclassification of the disease (gastroenteritis) may challenge the internal 
validity. Our definition of a gastroenteritis consultation included the two disease 
diagnoses D70 ‘Gastrointestinal infection’ and D73 ‘Gastroenteritis presumed infection’, 
and the symptom diagnosis D11 ‘Diarrhea’. This definition is in line with the Norwegian 
Syndromic Surveillance System (25), and was also used in a recently published study of 
antibiotic treatment for gastroenteritis in the Netherlands (88). The ICPC symptom 
diagnosis D10 ‘Vomiting’ was not included in the definition, although it is a common 
symptom in gastroenteritis it is probably less specific. As a result, consultations for 
diarrhea of other causes than gastroenteritis are included, but gastroenteritis consultations 
coded with D10 ‘Vomiting’ are missed. To my knowledge, studies on the validity of these 
diagnoses and the diagnostic algorithm are lacking. Reimbursement claims data have been 
shown to be informative in monitoring disease activity in primary care and promising in 
syndromic surveillance of gastrointestinal disease (29, 115, 116). 
Incorrect diagnosis coding in primary care is common (104), but the ICPC diagnoses 
correspond better with the patient record notes for consultations than for simple contacts 
with issuance of prescriptions (114). Different coding behavior in general practice and 
OOH services, as well as specific diagnosis being chosen to justify actions such as issuing 
sickness certificates or prescribing antibiotics, may cause differential misclassification 





5.2.1.5 Antibiotics as treatment for gastroenteritis 
In Paper II, we used antibiotics data based on courses dispensed from the pharmacies (as 
registered in NorPD). We do not have access to information about prescriptions, and thus 
do not know the indications for the treatment. Consequently, the indirect linking of 
dispensing to consultations may lead to possible misclassification of antibiotics as 
treatment for gastroenteritis. As a measure to minimize this, we did not include the 
following dispensations as treatment for gastroenteritis: 1) courses of antibiotics linked to 
consultations with co-diagnoses more likely to represent the real indication for the 
prescription, 2) courses of UTI antibiotics. Despite these measures, we believe that our 
study will include dispensed antibiotics that have been misclassified as treatment for 
gastroenteritis. The reason for this is that relevant co-diagnoses may not have been 
registered in the consultation, or the course might have been prescribed in consultations 
not included in the data material, such as telephone consultations, home visits, 
consultations with doctors outside primary care, or in consultations taking place between 
the gastroenteritis consultation and the dispensation. Lastly, antibiotic courses may also 
have been incorrectly defined as treatment for gastroenteritis if the consultation was 
misclassified as a gastroenteritis consultation. 
5.2.1.6 Gastroenteritis consultations instead of episodes 
The entity in Paper I and Paper II was gastroenteritis consultation, not gastroenteritis 
patient/case or gastroenteritis event. As a patient could have had several consultations 
during one gastroenteritis event, the results cannot be used for estimating the prevalence 
of gastroenteritis in the Norwegian population nor in primary care, nor can they be used to 
precisely estimate the extent of absence from work due to gastroenteritis.  
5.2.2 Paper III 
The main strength of this population-based cohort study was that data were collected 
during the acute phase of a large outbreak. This reduces recall bias considerably and 






5.2.2.1 Text message approach and selection bias 
The text message was sent by the municipality of Askøy on behalf of our research group. 
We do not know the exact number of text messages sent, how many who received the text 
message or, even less, how many were presented with the content of the message as all 
household members of the text message recipients were invited to participate. 
Consequently, we were not able to calculate an exact response rate for our survey.  
Selection bias is error due to systematic differences in characteristics between those who 
participate in a study and those who do not, and challenges the validity and 
generalizability of a study (118). Because the characteristics of non-participants are 
unknown to us, the presence of selection bias must be assumed (117). Selection bias 
leading to underrepresentation of children is suggested by our previous finding of 17 
patients under the age of 16 years in the study that characterized hospitalized patients 
during the same outbreak (111), whereas the present study includes no hospitalized cases 
under the age of 15 years. 
5.2.2.2 The consequences of time urgency 
This study of acute disease during an unforeseen waterborne outbreak could not have 
been planned in advance. We set up the study, got ethical approval and started data 
collection within two weeks after the outbreak was publicly known. This is a major 
strength of this study, but we later discovered some errors or limitations in the 
questionnaire: 1) unprecise phrasing of the questions regarding use of medication prior to 
the outbreak, 2) participants who were uncertain whether they were ill during the outbreak 
were not asked questions about symptoms. Consequently, we could not use the data on 
previous medication, nor categorize the uncertain group as cases or non-cases based on 
symptoms, as planned. 
5.2.2.3 Missing data 
Participants were per protocol asked to provide their national identity number, to allow 





chose not to give this information. Consequently, information about age and sex were 
missing for a considerable proportion of participants, as these data were extracted from 
the national identity number. All participants were asked about age and sex in later 
follow-up and we were able to update our database based on those answers. 
The group that was uncertain whether they had been ill had the greatest proportion of 
missing data for most variables, representing a group with more uncertain answers 
overall, whereas cases had the lowest proportion of missing data.  
5.2.2.4 Lack of clinical and microbiological data 
The study did not include any data from medical records or microbiological 
investigations. Thus, cases were neither verified by a clinician’s diagnosis nor by 
laboratory results. Using this population-based approach made it possible to investigate a 
broad spectrum of symptoms of gastroenteritis during a Campylobacter outbreak, but 
there is a risk that some cases were misclassified. Still, we believe that the main findings 
describe acute campylobacteriosis, as we expect a low probability for other causes of the 
gastroenteritis symptoms experienced by the cases in our study.   
Because we did not have variables to verify exposure to Campylobacter, such as detailed 
information on the drinking water supply, we could not investigate potential risk factors 
for developing acute disease during the outbreak. 
5.2.2.5 Definitions of ‘case’ and ‘severe gastroenteritis’ 
To our knowledge, there exist no common, symptom-based definitions of 
campylobacteriosis, gastroenteritis nor ‘severe gastroenteritis’ that are widely used for 
research purposes. Thus, our case definition was a modification of case definitions used in 
previous studies (15, 68, 69, 119), based on the participants’ self-reported information 
about their geographical presence, onset of illness and symptoms related to the outbreak. 
The symptom criteria in the case definition were quite wide, enabling the investigation of 
a broad spectrum of illness during the outbreak. Although this likely led to high 





The definition of ‘severe gastroenteritis’ was based on existing literature (71, 76, 78, 79), 
as well as clinical experiences and expertise among members in the research group, with 
the purpose to capture a greater extent of both local inflammation in the bowels (diarrhea 
for ≥ 5 days or bloody stools) and more generalized disease (fever > 2 days). We 
observed an association between this symptom-based ‘severe gastroenteritis’ outcome 
with both the self-reported perceived severity variable, and with the health care use 
variables, which to some extent suggests that our definition is valid.  
As the two definitions are based on self-reported symptoms, and 12% of the study 
population were uncertain whether they had been ill during the outbreak, we acknowledge 
that some participants probably have been misclassified (non-differentially) as ‘cases’ and 
with ‘severe gastroenteritis’ in our study.  
5.3 Interpretation of main findings 
5.3.1 Paper I 
The main findings in Paper I were that gastroenteritis consultations constitute 0.9% of all 
consultations in Norwegian primary care. There was a small increase in absolute number 
of gastroenteritis consultations, during the years 2006-15, that corresponds mainly with 
the increase in the Norwegian population during the same period. We observed a bi-
annual variation in gastroenteritis consultations, but this was not seen when organizing 
the data according to winter-summer variation. This likely reflects whether the main 
impact of winter vomiting disease (probably norovirus) hit the population before or after 
the shift of each year.  
Our study included consultations for gastroenteritis due to all possible pathogens. But the 
observed pattern of seasonality was in line with that known for norovirus infection on the 
European continent (120). The assumption that a majority of the consultations were due to 
norovirus infection, is supported by our findings of high consultation numbers for 
gastroenteritis among young children, and that the boys dominated in those under the age 





(29). Studies from Sweden (6) and the UK (3, 121) also present highest consultation rates 
among the youngest children. Further, young adults were the second most common 
patient group, suggesting transmission between child and carer supported by findings 
from an Australian population-based study of the risk of gastroenteritis (34). Rotavirus 
infection should be considered as one major cause of gastroenteritis among children under 
2 years of age, and a Norwegian study of hospitalized children reported rotavirus 
infections peaking in March through May (32). Rotavirus vaccination was introduced in 
Norway in 2014, at the end of our study period, thus we were not able evaluate any 
potential effect of the vaccine introduction based on one year of observations only.  
5.3.2 Paper II 
The main finding of Paper I was that the antibiotic treatment proportion in consultations 
for gastroenteritis in Norway was 1.8%. This is lower compared to findings presented in 
literature from other high-income countries (86-89, 122). Possible explanations for this 
may be low levels of bacterial and parasitic gastrointestinal infections in Norway, relative 
to viral infections (60, 123). Other explanations can be different health care seeking 
behavior, or that gastroenteritis cases with high risk of severe illness in Norway are 
hospitalized for treatment rather than managed in primary care. Of note, Norway 
generally has a low consumption of antibiotics (85).  
The antibiotic treatment proportion was higher in the OOH services compared to general 
practice, corresponding with studies from other European countries indicating higher 
antibiotic prescription rates in OOH services than in general practice for several infections 
(124-126). Possible reasons for this may be that the OOH services to a lesser extent offer 
follow-up, see patients with more severe illness and patients who, for various reasons, to a 
lesser extent are followed up by a GP.  
We observed a 16% reduction in antibiotic use in gastroenteritis consultations after year 





reduction) in Norway during the same period (127), and is in accordance with the goals of 
the Norwegian Action Plan from 2015 (101).  
Our finding of fluoroquinolones and metronidazole as the most frequently used antibiotics 
in the gastroenteritis consultations corresponds with findings in studies from primary care 
in the Netherlands, Switzerland and England (88, 122, 128). We have no explanations for 
the continuous increase in the use of metronidazole in gastroenteritis consultations after 
2012. However, as C. difficile infection has been notifiable to the Norwegian notification 
system (MSIS) after 2012 (129), and metronidazole is the first line treatment in primary 
care (25, 92), one could speculate whether this could be a contributing factor. Indeed, the 
number of C. difficile cases notified to MSIS did increase from 2013 (n=351) to 2015 
(n=2641), and appr. 35% were notified by GPs (129, 130). But still, the real incidence of 
C. difficile infections in Norway is uncertain due to non-compliance with the reporting 
obligation from the laboratories (43, 130). 
We found a lower prescription proportion among the youngest patients, a finding in line 
with a recent study from the Netherlands (88). This may be explained by higher 
gastroenteritis consultation frequency, and the higher likelihood of viral aetiology in 
younger patients, as accounted for in Paper I. 
Betalactamase sensitive penicillins were the third most frequently used, which may be 
surprising as they are not suitable for treatment of any gastrointestinal infections and thus 
defined as ‘not gastroenteritis relevant’ in our study. Compared to existing literature, a 
study of antibiotic treatment for gastroenteritis in primary care in the Netherlands did not 
include prescriptions of betalactamase sensitive penicillins (88), and betalactamase 
sensitive penicillins were found to account for 1.3% of antibiotic prescriptions for 
infections in the gastrointestinal tract in a study from the UK (128).  
A highly probable explanation to the frequent use of ‘not gastroenteritis relevant’ in our 
study is misclassification of disease and/or antibiotic treatment for gastroenteritis. Further, 





under 15 years of age, this may reflect more misclassification of disease in these age 
categories: Children pose a greater diagnostic challenge with high levels of co-infections 
and uncertain symptoms and findings. However, we cannot rule out the possibility that 
some doctors inappropriately prescribed the drug as a first line drug with the intention to 
treat gastroenteritis, as they are strongly advocated as the first choice antibiotics in 
treatment for several other infections commonly seen in primary care. 
Our finding of extensive use of CRP testing in gastroenteritis consultations with antibiotic 
treatment, adds to the findings in previous studies describing an extensive use of CRP 
testing in Norwegian primary care, especially in consultations with patients with 
suspected infection and in OOH services (107, 108, 131). Our study cannot explain this 
finding, as it did not include clinical information such as test results or information 
whether the tests affected the decision whether to prescribe antibiotics. 
5.3.3 Paper III 
The finding in Paper III of diarrhea and abdominal pain as the most common, and bloody 
stools and vomiting as the least common symptoms of acute gastroenteritis in the 
outbreak setting, is in line with previous literature on Campylobacter infection (59, 68, 
70, 72, 73, 77). Tiredness is a symptom that is non-specific to gastroenteritis, but still 
frequently reported in our study. We could not find descriptions of tiredness in published 
studies, probably because it is unspecific to gastroenteritis or Campylobacter infection. 
However, documenting the baseline level of the symptom at the time of the outbreak is 
useful to follow-up studies of post-infectious complaints, and should perhaps be 
investigated further in future outbreaks.   
We found a lower proportion of bloody stools among cases in our study (14%) compared 
to proportions ranging from 30-58% in studies of laboratory confirmed cases in general 
practice in the Netherlands (72), of sporadic notified cases in Norway (73), of laboratory 
confirmed cases aged 0-14 years in an outbreak in Greece (132), and notified cases in 





between age and bloody stools, that corresponds to our finding, although their proportions 
of bloody diarrhea among the youngest (59% in age < 5 years, 49% in 5-24 years) were 
higher than in our study (25.6% aged < 25 years, but none < 15 years). 
On the other hand, the proportion of bloody stools was higher in our study compared to 
two previous outbreak investigation studies: a population-based study of an outbreak in 
Røros, Norway (2%) (68), and in a study of cases included among patients seeking health 
care services (of which 16% were laboratory confirmed) during an outbreak in Finland 
(4%) (70). A reason for lower proportions of bloody stools reported in outbreak studies, 
including the present study, may be that they capture a broader scope of clinical features 
than represented by the laboratory confirmed cases. However, virulence factors associated 
with bloody stools of the different strains of Campylobacter, cannot be ruled out (111).   
Additionally, our finding was higher compared to the two previously published studies of 
the Askøy outbreak: NIPH’s population-based outbreak investigation study (6%) (68) and 
the study of hospitalized cases (9%) (110, 111). An explanation for a lower proportion of 
bloody stools observed in the latter study, can be a possible lowered threshold for referral 
due to fatal outcome in the initial phase of the outbreak, thus leading to hospitalization of 
less severe cases (111). The fact that NIPH’s outbreak investigation study was conducted 
at the very beginning of the outbreak only, and started a week earlier than our study, may 
be partly explain why NIPH found lower proportion of bloody stools as this symptom 
usually develops during days after infection.  
In our study, joint pain was more common compared to the findings in a Norwegian study 
of sporadic campylobacteriosis from 1992 (50% vs. 27%) (73), but otherwise seems to be 
scarcely described as a symptom during the acute phase of Campylobacter infection in 
existing literature.  
Median duration of illness observed in our study (6 days) is consistent with what is 
commonly reported in previous studies (5-6 days) (68, 70, 77), except for the Norwegian 





A total of three per cent, none under the age of 15 years, and 30% of the hospitalized 
cases in our study were treated with antibiotics, whereas the study of hospitalized patients 
during the same outbreak found that one in two of children and one in ten of adults 
received antibiotics (111). A Norwegian study from 1992 reported that 16% of 135 
sporadic laboratory confirmed cases in Norway were treated with antibiotics (73), White 
et al. 2019 reported an antibiotic treatment proportion of 35% in culture confirmed cases 
in Australia, Canada and the United States (77). However, neither of these previous 
studies discriminated between treatment proportions in hospitalized and non-hospitalized 
patients. The low antibiotic treatment proportion found in our study is in line with the 
Norwegian recommendations, and with a generally cautious policy regarding use of 
antibiotics in Norway (25, 71, 92, 97). 
In Paper III, we identified high consumption of tap water, having depression or peptic 
ulcer prior to the outbreak as risk factors associated with severe gastroenteritis, whereas 
being in the age category 35-44 seemed to be protective. The association between high 
consumption of tap water and severe gastroenteritis is not surprising as the outbreak was 
waterborne, and probably indicates a dose response relationship. The association between 
depression and severe gastroenteritis is supported by a previous study showing that 
psychological comorbidity increased susceptibility to develop gastroenteritis during a 
waterborne outbreak in Belgium (84). However, bias may lead to reporting of more 
severe symptoms in cases with self-reported depression, as the symptom pressure can be 
perceived as more burdensome in this patient group. Peptic ulcer as a risk factor for 
severe illness is reasonable, as a gastrointestinal disease, and not least presumably often 







Through the three sub-studies that comprise this thesis, we have documented that 
gastroenteritis consultations in Norwegian primary care exhibit an epidemiological 
pattern and seasonal variation in line with a dominance of viral infections. 
Antibiotic treatment is infrequently used in gastroenteritis consultations in Norway. There 
was a decrease in overall use of antibiotics in gastroenteritis consultations after 2012, 
which coincides with an observed reduction in the total use of antibiotics due to any cause 
in Norway during the same period.  
The clinical features of self-reported acute gastroenteritis during a large waterborne 
Campylobacter outbreak exhibits a broader spectrum of symptoms than the descriptions 





7. Further research 
Future research to further improve the understanding of management of gastroenteritis 
patients in primary care should include clinical data from consultations, such as 
symptoms and severity of illness, travel history, information about stool sampling and 
results and antibiotic prescribing.  
Also, further research is needed to investigate any benefits of point-of-care CRP testing 
for management of gastroenteritis patients, including whether the tests affect the decision 
whether to prescribe antibiotics.  
More detailed information about time and geography of the consultations would be useful 
in future studies of the syndromic surveillance and antibiotic treatment of gastroenteritis. 
By including information that verifies exposure to the source of infection, research studies 
on future gastroenteritis outbreaks can investigate risk factors for developing acute illness 
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Abstract
Background. Most of the patients with gastroenteritis seeking health care services are managed 
in primary care; yet, little is known about these consultations. Syndromic-based surveillance of 
gastrointestinal infections is used in several countries, including Norway.
Aim. To investigate the extent of, and explore characteristics associated with, consultations for 
gastroenteritis in primary care and to compare consultations in daytime general practice and out-
of-hours (OOH) services in Norway.
Design and Setting. Registry-based study using reimbursement claims data from all consultations 
in general practice and OOH services in Norway over the 10-year period, 2006–15.
Methods. The main outcome variable was whether the consultation took place in general practice 
or OOH services. Possible associations with patient age and sex, time and use of point-of-care 
C-reactive protein (CRP) testing and sickness certificate issuing were investigated.
Results. Gastroenteritis consultations (n  =  1  281  048) represented 0.9% of all consultations in 
primary care (n  = 140 199 637), of which 84.4% were conducted in general practice and 15.6% 
in OOH services. Young children and young adults dominated among the patients. Point-of-care 
CRP testing was used in 36.1% of the consultations. Sickness certificates were issued in 43.6% of 
consultations with patients in working age. Age-specific time variations in consultation frequencies 
peaking in winter months were observed.
Conclusions. The proportion of gastroenteritis consultations was higher in the OOH services when 
compared with daytime general practice. Young children and young adults dominated among the 
patients. The seasonal variation in consultation frequency is similar to that shown for gastroenteritis 
caused by norovirus.
Key words:  Epidemiology, gastroenteritis, general practice, health services research, primary health care.
Background
Gastroenteritis is an inflammation of the gastrointestinal tract caused 
by a pathogenic microbe. A common, symptom-based definition of a 
gastroenteritis case is an individual who experiences ≥3 loose stools, 
or any vomiting, in 24 hours, excluding cases where these symptoms 
are explained by known noninfectious reasons (1). Gastroenteritis is 
one of the leading causes of morbidity and mortality in low-income 
countries (2). In high-income countries, gastroenteritis is rarely le-
thal, and most patients experience self-limiting symptoms without 
seeking medical care (3–6). Still, in these countries, gastroenteritis 
has considerable socioeconomic costs (3, 7) and is of public health 
interest as the condition tends to appear in outbreaks (8–10).
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The agents causing gastroenteritis include a variety of viruses, 
bacteria, parasites and toxins. Stool samples are generally not sub-
mitted from primary care as most infections resolve in a few days 
without treatment. When stool samples are submitted, the infective 
agent is most commonly either viral or not identified (11–14). Spread 
of infections through international travel is of concern (15), and sev-
eral of the microbes known to cause gastroenteritis are on the WHO 
priority list of antibiotic-resistant bacteria (16). Previous studies de-
scribe trends in seasonality for different agents causing gastroenter-
itis (17–23), although studies of seasonal trends in gastrointestinal 
infections in primary care are lacking.
Infectious disease surveillance systems are traditionally based 
on laboratory-confirmed cases. However, near real-time syndromic-
based surveillance systems based on data from primary care that 
are not laboratory confirmed are established in several European 
countries, including Norway (24, 25). In the Norwegian Syndrome 
Surveillance System (NorSySS), gastroenteritis is defined by the ICPC 
diagnoses ‘D11 Diarrhoea’, ‘D70 Gastrointestinal infection’ and 
‘D73 Gastroenteritis, presumed infection’.
Most of the consultations in primary care in Norway are carried 
out in the general practice surgery during opening hours, including 
daytime emergency consultations. Additionally, emergency medical 
services are organized as out-of-hours (OOH) services either with 
general practitioners on duty in the municipalities, or as 24-hour 
emergency services in some of the larger cities.
When individuals with gastroenteritis seek health care, they 
are generally managed in primary care. Yet, little is known about 
these consultations in terms of prevalence in primary care, patient 
characteristics and seasonal variations. Scientific knowledge about 
gastroenteritis in primary care is useful for clinicians, public health 
professionals interpreting surveillance data and for health service 
planners.
The aims of this study were to investigate the extent of, and ex-
plore characteristics associated with, consultations for gastroenter-
itis in primary care and to compare consultations in daytime general 
practice and OOH services in Norway.
Materials and methods
All residents in Norway are entitled to have a general practitioner 
(GP) as part of the national public health care system. The GPs are 
the first port of call, provide comprehensive care and act as gatekeep-
ers to secondary care. Point-of-care C-reactive protein (CRP) testing 
is widely used in general practice and OOH services in Norway.
Doctors in general practice and OOH services send reimburse-
ment claims electronically to the Norwegian Health Economics 
Administration (HELFO). The reimbursement claims include infor-
mation about the doctor (ID-number) and patient (unique personal 
identifier and sex), date and time for the contact and diagnoses for 
each contact. The reimbursement claims also contain information 
on actions such as point-of-care CRP testing and issues of sickness 
certificate as part of the individual consultations, as these actions are 
reimbursed.
The data from the reimbursement claims are registered prospect-
ively in real-time and collected in the national KUHR database. 
In this study, we used data from KUHR from all consultations by 
attendance in general practice and OOH services during the 10-year 
period, 2006–15. Daytime activity data from work days from the 
24-hour emergency services in Bergen (the second largest city in the 
country) are not included in this study, as they are not registered in 
the KUHR database.
Variables
We defined a consultation as a patient’s physical encounter with a 
doctor, focusing on clinical cases being eligible to further exami-
nation and treatment. Consultations made electronically, by home 
visits or telephone were not included in this study. We defined a ‘gas-
troenteritis consultation’ as a consultation with one or more of the 
following ICPC codes: ‘D11 Diarrhoea’, ‘D70 Gastrointestinal infec-
tion’ and ‘D73 Gastroenteritis, presumed infection’, which are the 
codes defining gastroenteritis in NorSYSS (25).
The registry predefines type of service, and we could further 
categorize this variable into ‘general practice’ and ‘OOH service’. 
We categorized patient age into the following ten categories: 0–4, 
5–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and 
≥85 years. Patient sex is predefined in the registry. Due to privacy 
concerns, the Norwegian Data Protection Authority would only 
accept quarter of a year as the most detailed level of the time vari-
able for this study. Quarter refers to time period of year for the con-
sultations as follows: January–March, April–June, July–September 
and October–December. We further categorized time period into 
summer (combining April–June and July–September quarters) and 
winter seasons (combining October–December and January–March 
quarters). For the analyses of sickness certificate issues, we included 
consultations with patients aged 20–67 years only.
Statistics
The data were analysed using Stata/MP 15.0 for Windows and 
Microsoft Excel 2010 for frequency and bivariate analyses.
We calculated the proportion of gastroenteritis consultations as 
the percentage of total consultations for any diagnosis. The main 
outcome variable was whether the consultations took place in 
general practice or in the OOH services. Possible associations with 
patient age and sex, time of year for the consultations, use of point-
of-care CRP testing and sickness certificate issuing in the consulta-
tions were investigated by bivariate statistics. The high numbers of 
observations in the data material made even small differences and 
associations significant at the <.05 significance level.
Results
Over the 10-year period, 2006–15, there were 140 199 637 consul-
tations in primary care in Norway. Of these, 127 389 382 (90.9%) 
were in general practice and 12  810  255 (9.1%) in OOH ser-
vices. There were 1 281 048 gastroenteritis consultations: of these 
1 081 774 (84.4%) were conducted in general practice and 199 274 
(15.6%) in the OOH services. This constitutes 0.9% of all consulta-
tions in primary care, corresponding to 0.8% of consultations in 
general practice and 1.6% of consultations in the OOH services.
Key Messages
• Consultations for gastroenteritis represented 0.9% of all consultations.
• Young children and young adults were the most common patients.
• Number of consultations for gastroenteritis was higher in winter months.
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Female patients contributed to 57.9% of consultations for any 
diagnosis: 58.4% in general practice and 52.5% in OOH services. 
The sex difference was less pronounced in the gastroenteritis consul-
tations, with 52.8% female patients: 53.2% in general practice and 
50.5% in OOH services (Table 1).
Mean patient age was 46.1 years for consultations for any diag-
nosis: 47.2  years in general practice and 35.1  years in OOH ser-
vices (Table 1). Patients aged 55–64 years had the highest number 
of consultations (14.2%). Mean age was 32 years for the patients 
in gastroenteritis consultations: 33.6 years in general practice and 
22.8  years in OOH services (Table 1). Children aged 0–4  years 
accounted for the highest number of gastroenteritis consultations, 
followed by young adults aged 25–34 years, in general practice and 
OOH services (Fig. 1).
Sex distribution by age for consultations with any diagnosis 
in primary care showed a majority of boys in the two lowest age 
categories 0–4 years (54.3%) and 5–14 years (50.7%): 54.0% and 
50.4%, respectively, in general practice, and 55.2% and 52.2%, 
respectively, in OOH services. This finding was also observed for the 
gastroenteritis consultations in primary care (55.5% and 55.6% for 
the two age groups, respectively): both in general practice (55.9% 
and 56.4%) and OOH services (54.5% and 52.9%).
The numbers of all consultations for any diagnosis increased 
steadily every year over the 10-year period, from 12 295 867 con-
sultations in 2006 to 15  185  884 consultations in 2015 (23.5% 
increase). This increase was seen in both general practice and OOH 
services until 2012, but in the following years, there was a slight 
decrease in the number of consultations in OOH services. Mean 
annual number of gastroenteritis consultations was 128  104, and 
the overall trend in number of gastroenteritis consultations was an 
increase from 120 624 in 2006 to 133 091 consultations in 2015 
(10.3% increase). However, the proportion of gastroenteritis consul-
tations decreased from 1% in 2006 to 0.9% in 2015, due to an even 
higher increase in consultations for any diagnosis.
The number and proportion of gastroenteritis consultations 
showed a bi-annual cycle through the whole period. This pattern of 
Table 1. Characteristics of consultations for any diagnosis and for gastroenteritis in primary care (general practice and OOH services) in 
Norway 2006–15
 Consultations for any diagnosis Gastroenteritis consultations
GP + OOH GP OOH GP + OOH GP OOH
n % n % n % n % n % n %
Total 140199637 100a 127389382 90.9a 12810255 9.1a 1281048 100a 1081774 84.4a 199274 15.6a
Sex
 Male 59049592 42.1 52958422 41.6 6091170 47.6 604732 47.2 506176 45.8 98556 49.5
 Female 81149996 57.9 74430921 58.4 6719075 52.5 676314 52.8 575597 53.2 10717 50.5
 Missing 49  39  10  2  1  1  
Age (years)
 Mean age 46.1 47.2 35.1 32 33.6 22.8
 0–4 7469970 5.3 5699054 4.5 1770916 13.8 272460 21.3 197329 18.2 75131 37.7
 5–14 8044813 5.7 6632863 5.2 1411950 11.0 99295 7.8 76687 7.1 22608 11.4
 15–24 12912593 9.2 10962960 8.6 1949633 15.2 159053 12.4 134797 12.5 24256 12.2
 25–34 17936332 12.8 16204321 12.7 1732011 13.5 210226 16.4 185194 17.1 25032 12.6
 35–44 19466283 13.9 17906604 14.1 1559679 12.2 157587 12.3 142206 13.2 15381 7.7
 45–54 19361034 13.8 18077251 14.2 1283783 10.0 121612 9.5 111026 10.3 10586 5.3
 55–64 19962550 14.2 18834073 14.8 1128477 8.8 108508 8.5 99578 9.2 8930 4.5
 65–74 16469661 11.8 15611736 12.3 857925 6.7 74381 5.8 67453 6.2 6928 3.5
 75–84 13145913 9.4 12430614 9.8 715299 5.6 54530 4.3 48060 4.4 6470 3.3
 85– 5430438 3.9 5029866 4.0 400572 3.1 23394 1.8 19443 1.8 3951 2.0




36239587 25.9 33101417 26.0 3138170 24.5 375655 29.3 315345 29.2 60310 30.3
 April–June 34630198 24.7 31357589 24.6 3272609 25.6 296551 23.2 244100 22.6 52451 26.3
  July– 
September
32226854 23.0 29069703 22.8 3157151 24.7 288290 22.5 246625 22.8 41665 20.9
  October– 
December
37102998 26.5 33860673 26.6 3242325 25.3 320552 25.0 275704 25.5 44848 22.5
CRP
 Yes 21663935 15.5 17534547 13.8 4129388 32.2 462609 36.1 348200 32.2 114409 57.4
 No 118535702 84.6 109854835 86.2 8680867 67.8 818439 68.9 733574 67.8 84865 42.6
Sickness cert.b
 Yes 20658152 23.1 19997369 24.2 660783 9.3 320313 43.6 300743 45.9 19570 24.8
 No 68938272 76.9 62522490 75.8 6415782 90.7 414071 56.4 354848 54.1 59223 75.2
 Total 89596424 100 82519859 100 7076565 100 734384 100 655591 100 78793 100
Distribution within sex, age, season, centrality, point-of-care CRP and sickness certificate is given by column if not otherwise stated.
aDistribution of service type (GP and OOH services) within consultations for any diagnosis and gastroenteritis consultations, respectively
bAnalyses of sickness certificate are restricted to patients aged 20–67 years.
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variation was observed for both general practice and OOH services 
(Fig. 2), and most pronounced for the age category 0–4 years in both 
service types (data not shown). To further investigate this pattern, 
we organized the data according to winter and summer seasons, as 
the shift of the year splits each winter season. These analyses did not 
show a similar bi-annual cycle from one winter season to the next 
(data not shown).
Quarterly distribution of consultations for any diagnosis in pri-
mary care was nearly equal throughout the four quarters, although 
slightly more of the consultations were observed during the months 
October–December (26.5%) and January–March (25.9%). In con-
trast, gastroenteritis consultations peaked during January–March 
(29.3%) followed by October–December (25.0%), both in general 
practice and OOH services (Table 1). This variation for gastroenteri-
tis consultations by quarter was most evident for the age categories, 
0–4, 5–14 and 25–34 years (Fig. 3). For other age groups, the num-
ber of gastroenteritis consultations in both service types was more 
equally distributed through the quarters.
Point-of-care CRP testing took place in 15.5% of the consulta-
tions for any diagnosis: in 13.8% of the consultations in general 
practice and in 32.2% of the consultations in the OOH services 
(Table 1). Among gastroenteritis consultations, point-of-care CRP 
testing was used in 36.1% of the consultations: in 32.2% of the con-
sultations in general practice, when compared with 57.4% in OOH 
services (Table 1).
Among patients in the working age (age group 20–67 years), sick-
ness certificates were issued in 23.1% of the consultations with any 
diagnosis: 24.2% in general practice and 9.3% in the OOH services 
(Table 1). Sickness certificates were issued in 43.6% of the gastroenter-
itis consultations: 45.9% in general practice and 24.6% in OOH ser-
vices (Table 1). We observed an equal sex distribution among patients 
in gastroenteritis consultations with sickness certificates issued in both 
general practice and OOH services (data not shown).
Discussion
Summary
Gastroenteritis consultations represented 0.9% of all consultations by 
encounter in primary care in Norway during the years 2006–15, of 
which 84.4% took place in general practice and 15.6% in OOH ser-
vices. The number of gastroenteritis consultations was higher during 
the winter months with little change from one winter season to the 
next. The most common patient was either a young child or young 
adult, with young children dominating even more so in the OOH ser-
vices. These two age groups also contributed the most to the observed 
peak in number of gastroenteritis consultations in the winter months.
Strengths and limitations
A main strength of this study was the use of complete registry data 
from nearly all consultations in general practice and OOH services in 
Figure 2. Gastroenteritis consultations in primary care by year and service type [general practice (GP) and OOH services]. Norway, 2006–15. Total number of 
gastroenteritis consultations = 1281048.
Figure 1. Number of gastroenteritis consultations in primary care by age group and service type [general practice (GP) and OOH services]. Norway, 2006–15. 
Total number of gastroenteritis consultations = 1281046 (2 missing).
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Norway, thereby considerably reducing selection bias. Reimbursement 
claims data have been shown to be informative in monitoring disease 
activity in primary care, and promising in syndromic surveillance of 
gastrointestinal disease but yet having low sensitivity and low positive 
predictive value in detecting outbreaks (14, 26, 27). The current study 
has some limitations. A part of reimbursement claims from the 24-hour 
emergency services in Bergen (daytime consultations from work days) 
are not reported, leading to a minor underreporting of consultations 
in OOH services. Further, claims from consultations by e-mail, home 
visits and telephone were not included in the current study. Due to the 
nature of gastroenteritis as a contagious disease, we believe that the 
use of telephone consultations is considerable, but probably more for 
administrative purposes, such as sickness certificates, than for disease 
management. The lack of telephone consultations and home visits may 
challenge the external validity specifically in the context of syndromic 
surveillance, as our findings do not reflect the total activity in primary 
care. However, this study was designed to analyze the face-to-face con-
sultation activity concerning gastroenteritis. Another limitation is the 
lack of precision in the time variable. Ideally for the analyses of sea-
sonality, we should have had information about the exact date or week 
number for the consultations.
Possible misclassification of the disease (gastroenteritis) may 
challenge the internal validity. Awareness of different coding behav-
iour in general practice and OOH services, as well as specific diag-
nosis being chosen to justify actions (e.g. sickness certificate), is 
important in interpreting the data. Our definition of a gastroenteritis 
consultation including D11 ‘Diarrhoea’, but not D10 ‘Vomiting’, is 
not completely in line with a common definition (1), but was chosen 
to be in line with the definition used by the Norwegian Syndromic 
Surveillance System (25). As a result, consultations for diarrhoea of 
other causes than gastroenteritis are included, but gastroenteritis 
consultations coded with D10 ‘Vomiting’ are missed. Studies on the 
validity of these diagnoses and the diagnostic algorithm are lacking.
The perspective of this study was from the health care services, 
and the entity in the study was the consultation for (not patients 
with) gastroenteritis. Thus, it cannot be used for estimating the prev-
alence of gastroenteritis in the Norwegian population nor in pri-
mary care. Also, it cannot be used to precisely estimate the extent of 
absence from work due to gastroenteritis.
Interpretation/comparison with existing literature
Many gastrointestinal infections exhibit some kind of seasonality 
(28) and the mechanisms of seasonality are thought to vary for 
the different pathogens (20), including factors such as variability 
in temperature and humidity, start of school year, geographical lo-
calization on either Northern or Southern Hemisphere and level 
of country development (19,21,23). Norovirus infections seem 
to have a seasonal pattern with peaks in the cooler months, i.e. 
December through February in the Northern Hemisphere and June 
through August in the Southern Hemisphere (17, 29). The present 
study includes gastroenteritis due to all possible pathogens, but the 
observed pattern of seasonality is in line with that known for noro-
virus infection on the European continent (30). Also, our findings 
of high consultation numbers for gastroenteritis among young chil-
dren, and that the boys account for the majority of gastroenter-
itis consultations among those under the age of 15  years, are in 
line with a Dutch study of norovirus infection in primary care (14). 
Studies from Sweden (3) and the UK (13, 31) also present high-
est consultation rates among the youngest children. Our findings 
of young adults as the second most common patient group suggest 
transmission between child and carer supported by findings from 
an Australian population-based study of the risk of gastroenteritis 
(20). Rotavirus infection should be considered as one major cause 
of gastroenteritis among children under 2 years of age. In older chil-
dren and in adults, rotavirus most often presents as asymptomatic 
or subclinical reinfections. A Norwegian study of hospitalized chil-
dren reported rotavirus infections peaking in March through May 
(18). Rotavirus vaccination was introduced in Norway in 2014 (at 
the end of our study period); thus, we were not able to evaluate 
any potential effect of the vaccine introduction based on 1 year of 
observations only.
We observed a bi-annual variation in gastroenteritis consulta-
tions, but this was not seen when organizing the data according 
to winter–summer variation. This likely reflects whether the main 
impact of winter vomiting disease (probably norovirus) hit the popu-
lation before or after the shift of each year.
During the 10-year period, there was a small increase in the 
absolute number of gastroenteritis consultations. This corresponds 
mainly with the increase in the Norwegian population during the 
same period.
Our finding of a higher proportion of point-of-care CRP test-
ing in consultations for gastroenteritis in OOH services when com-
pared with general practice has also been described in a previous 
Norwegian study (32). We find the use of CRP surprisingly high, but 
we do not have clinical information about the reason for the testing, 
nor the results of these tests.
Figure 3. Number of gastroenteritis consultations in primary care (general practice and OOH services) by age group and quarter of a year. Norway, 2006–15. 
N = 1281047 (1 missing).
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Implications for clinical care and research
To the best of our knowledge, this is the first study to present com-
plete national registry data on gastroenteritis patients’ encounters 
with primary care doctors over a 10-year period. The results of this 
study are highly relevant when interpreting data for syndromic sur-
veillance of gastroenteritis based on routine data from primary care. 
Increased knowledge of the typical patients (age and sex) expected to 
be seen in consultations for gastroenteritis throughout the year and 
service type would be useful for the doctors managing the patients 
in primary care. We think that our results are generalizable at least 
to countries in the Northern Hemisphere with a primary care system 
similar to Norway. Future research should study illness trajecto-
ries in patients with gastroenteritis managed in primary care. More 
detailed information about time and geography of the consultations 
would be useful in future studies of the syndromic surveillance of 
gastroenteritis. Adding clinical data from the consultations, such as 
symptoms and severity, and information about stool sampling and 
results, would further improve the understanding of gastroenteritis 
in primary care. Also, further research is needed to investigate any 
benefits of point-of-care CRP-testing for gastroenteritis.
In conclusion, the proportion of gastroenteritis consultations was 
higher in the OOH services when compared with daytime general 
practice. The most frequent patients with gastroenteritis in primary 
care were young children and young adults, with young children 
dominating even more so in the OOH services. The observed sea-
sonal variation in consultations frequency is similar to that shown 
for gastroenteritis caused by norovirus on the Northern Hemisphere. 
These results should be useful for health service planners as well as 
surveillance systems and clinicians in countries with a comprehen-
sive primary care system.
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Abstract
Background: When patients with gastroenteritis (GE) seek health care, they are generally managed 
in primary care. Little is known about the use of antibiotic treatment in these cases.
Objective: The aim of this study was to investigate time trends and patient characteristics 
associated with antibiotic treatment for GE in Norwegian primary care in a 10-year period.
Methods: We linked data from two nationwide registries, reimbursement claims data from 
Norwegian primary care (the KUHR database) and The Norwegian Prescription Database, for the 
period 2006–15. GE consultations were extracted, and courses of systemic antibiotics dispensed 
within 1 day were included for further analyses.
Results: Antibiotic treatment was linked to 1.8% (n = 23 663) of the 1 279 867 consultations for 
GE in Norwegian primary care in the period 2006–15. The proportion of GE consultations with 
antibiotic treatment increased from 1.4% in 2006 to 2.2% in 2012 and then decreased to 1.8% in 
2015. Fluoroquinolones (28.9%) and metronidazole (26.8%) were most frequently used. Whereas the 
number of fluoroquinolones courses decreased after 2012, the number of metronidazole courses 
continued to increase until year 2015. The antibiotic treatment proportion of GE consultations was 
lowest in young children and increased with increasing age.
Conclusion: Antibiotic treatment is infrequently used in GE consultations in Norwegian primary 
care. Although there was an overall increase in use during the study period, we observed a reduction 
in overall use after year 2012. Young children were treated with antibiotics in GE consultations less 
frequent than older patients.
Key words: Antibiotics, consultation, gastroenterology, health services research, infectious diseases, primary care.
Introduction
Gastroenteritis (GE) is a common disease worldwide. In high-income 
countries, most episodes of GE are self-limiting without need of med-
ical attention (1–4). Those seeking health care services are generally 
managed in primary care, accounting for about 130 000 consultations 
(0.9% of all primary care consultations) annually in Norway (5).
Studies from Northern European countries have shown that in 
primary care the infective agents are most commonly either viruses 
or cannot be identified (6–9). Norwegian guidelines and international 
recommendations state that antibiotics should be avoided for the 
treatment of GE in primary care (10,11). For most causal microbes, 
antibiotics are not shown to shorten the symptomatic phase of GE 
and, in some cases, could contribute to a more serious outcome 
(12,13). However, specific antibiotic treatment is recommended for 
certain gastrointestinal infections, especially in the hospital setting 
(11,14). In 2015, the Norwegian Government launched the Action 
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Plan to Fight Antimicrobial Resistance in the Health Care Services 
(15), with the target of reducing total sales of antibiotics in human 
medicine by 30% within the year 2020 when compared with the level 
in 2012 (16). By 2015, an 11% reduction was already observed (17).
In high-income countries, GE is seldom treated with antibiotics 
in primary care, with prescribing proportions ranging from 5% to 
11% varying between countries (18–22). In the current study, we 
use complete national registry data with the aim to investigate time 
trends and patient characteristics associated with antibiotic treat-
ment for GE in Norwegian primary care from 2006 to 2015.
Materials and methods
Primary care in Norway
All residents in Norway are entitled to be on the patient list of a 
GP, and 99% of the population was registered to this service in 
2015 (23). Most consultations in primary care, including daytime 
emergency consultations, are carried out in general practice sur-
geries during regular opening hours. In addition, emergency med-
ical services are organized as out-of-hour (OOH) services with GPs 
on duty in the municipalities or as 24-hour emergency services in 
larger cities. In the management of infectious diseases, point-of-care 
C-reactive protein (CRP) testing is widely used in general practice 
and OOH services in Norway (24). GPs play a key role in certifying 
all sorts of sickness absence. Most employees will need documen-
tation from a physician for sick leave exceeding three days. For in-
fection control reasons, it is advised to issue sickness certificates to 
GE patients in specific work situations independent of the clinical 
manifestation and possible loss of function (food production and 
preparation, patient contact) (25).
We linked data from two national registries for the 10-year 
period 2006–15: Reimbursement claims data from Norwegian pri-
mary care (the KUHR database) and the Norwegian prescription 
database (NorPD).
The KUHR database
Reimbursement claims data from both daytime general practice and 
OOH services are registered in the national KUHR database. The 
reimbursement claims include information about service type (gen-
eral practice or OOH service), patient (unique personal identifier 
defining age and sex) and time for the consultation and diagnoses 
(International Classification for Primary Care [ICPC-2] codes) for 
each contact. Reimbursed procedures, such as point-of-care CRP 
testing and issuing of sickness certificates, are also included in these 
data, whereas no specific codes exist for microbiological testing of 
stool samples.
In this study, we used data from all consultations by attendance 
in general practice and OOH services. Home visits, and consult-
ations made electronically or by telephone, were not included in the 
data set extracted from KUHR. For administrative reasons, daytime 
activity data from the 24-hour emergency services in Bergen (the 
second largest city in the country with 5% of the total population) 
are not registered in the KUHR database, and thus not part of 
this study.
We defined a gastroenteritis consultation (‘GE consultation’) 
as a consultation with one or more of the following ICPC-2 
codes: ‘D11 Diarrhoea’, ‘D70 Gastrointestinal infection‘ and ‘D73 
Gastroenteritis, presumed infection’. ‘D70 Gastrointestinal infection’ 
represent the most detailed level of diagnostic codes for gastrointes-
tinal infections. We categorized patient age in the KUHR database 
into the following 10 categories: 0–4, 5–14, 15–24, 25–34, 35–44, 
45–54, 55–64, 65–74, 75–84 and ≥85 years.
The Norwegian Prescription Database
The NorPD is a complete registry of all prescription drugs dispensed 
from pharmacies in Norway. Drugs used for treatment of inpatients 
in hospitals and nursing homes are not registered in NorPD. NorPD 
contains information about the patient (pseudonym unique per-
sonal identifier), time for dispensing and information about the 
drug [Anatomical Therapeutic Chemical (ATC) classification system 
code]. We used data from the NorPD for all prescribed systemic 
antibiotic courses dispensed from pharmacies in Norway during the 
10-year period, 2006–15.
We defined ‘course of antibiotics’ as a course of a prescribed sys-
temic antimicrobial drug dispensed from a pharmacy and registered 
in the NorPD with the following ATC codes: ‘J01 Antibacterials for 
systemic use’, ‘A07AA09 Vancomycin’ or ‘P01AB01 Metronidazole’. 
We categorized antibiotics as either ‘GE relevant’ or ‘not GE rele-
vant’, as we found it necessary to make this divide to further inter-
pret the data. According to Norwegian and international guidelines, 
we defined the following antibiotics as relevant for treatment of 
gastrointestinal infections (‘GE relevant’): fluoroquinolones, metro-
nidazole, macrolides, tetracycline, trimethoprim-sulphamethoxazole 
and vancomycin. All other antibiotics were defined as ‘not GE rele-
vant’. When a GE consultation is linked to ‘not GE relevant’ anti-
biotics this can result from both inappropriate prescribing and 
misclassification in our data set (for example prescribing made for 
other diseases than GE). Additionally, we defined the following as 
urinary tract infection antibiotics (‘UTI antibiotics’), as their only 
indication is UTI: pivmecillinam, mecillinam, trimethoprim, nitro-
furantoin and metenamin.
Linking of data sets
The consultation data from the KUHR database were linked to the 
drug prescription data from NorPD by the patients’ pseudonym 
unique personal identifiers.
Due to privacy concerns, the Norwegian Data Protection 
Authority would not accept original dates coupled with patient data. 
These were therefore replaced by Statistics Norway with a random 
reference date unique for each patient, from which the time of each 
registration in this dataset refers to.
A course of antibiotics was considered as linked to a consult-
ation in primary care when the prescribed drug was dispensed from 
the pharmacy at the same day or the day after the consultation. We 
Key Messages
• Antibiotics for gastroenteritis are infrequently used in Norwegian primary care.
• Antibiotics usage increased from 2006 to 2012, followed by decrease through 2015.
• Metronidazole and fluoroquinolones were most frequently used.
• Children were least frequently treated with antibiotics for gastroenteritis.
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extracted all GE consultations, and the courses of antibiotics linked 
to these consultations, for analyses. Both antibiotics defined as ‘GE 
relevant’ and ‘not GE relevant’ were included as treatment for GE in 
the analyses, except for the following two categories: (i) Courses of 
antibiotics (both ‘GE relevant’ and ‘not GE relevant’) linked to con-
sultations with a co-diagnosis (other than D11, D70 or D73) likely 
to explain the prescription (Supplementary Table S1) and (ii) courses 
of ‘UTI antibiotics’. These courses were excluded as treatment for 
GE, and consultations linked to these were included as GE consult-
ations without antibiotic treatment in the analyses (Fig. 1).
Statistics
We calculated the proportion of GE consultations that were followed 
by antibiotic treatment. Patient characteristics, use of CRP and issuing 
of sickness certificates were compared between GE consultations with 
and without antibiotic treatment and between GE consultations in 
general practice and in OOH services. We explored time trends in the 
use of different antibiotics as treatment for GE. The data were ana-
lysed using StataSE 16.1 and Microsoft Excel for Windows 365 MSO.
Results
There were 1 279 867 GE consultations in Norway in the period 
2006–15, of which 84.5% (n = 1 081 162) were in general practice 
and the rest in OOH services.
Antibiotic treatment was linked to 1.8% (n = 23 663) of the GE 
consultations (Table 1), after excluding the following as GE consult-
ations with antibiotic treatment not for GE: 3956 consultations with 
a co-diagnosis more relevant to the prescription (of these, 2076 were 
an R-diagnosis in ICPC-2, indicating a respiratory tract infection), 
and 2926 consultations linked to courses of UTI antibiotics (Fig. 1). 
In general practice, the proportion of GE consultations with anti-
biotic treatment was 1.8% (n = 19 617), and in the OOH services, 
the proportion was 2.0% (n = 4046).
The number of GE consultations with antibiotic treatment in-
creased by 78.4% from 1636 in 2006 to 2918 in 2012, followed by a 
16% decrease from 2012 until 2015. A similar pattern was observed 
for the proportion of GE consultations with antibiotic treatment, 
which increased from 1.4% in 2006 to 2.2% in 2012 and then de-
creased to 1.8% in 2015 (Fig. 2).
There was no difference between the sexes in proportions of GE 
consultations with antibiotic treatment (data not shown). The pro-
portion of GE consultations with antibiotic treatment was lowest in 
patients aged 0–4 years (1.0%) and increased with increasing age 
up to the categories 55–64 and 65–74 years (3.0%). This trend was 
even more pronounced in the OOH services (Fig. 3).
CRP testing was used in 58.1% of the GE consultations with 
antibiotic treatment, when compared with 35.7% without antibiotic 
treatment (Table 1). CRP testing was used more frequently in OOH 
services than in general practice, this applied to both GE consult-
ations with antibiotic treatment and without (Table 1). The propor-
tion of CRP testing in GE consultations with antibiotic treatment 
increased from 52.4% in 2006 to 60.8 % in 2012 but remained 
stable for the years 2012–15 (data not shown).
Most of the GE consultations with antibiotic treatment were linked 
to single courses of antibiotics (90.3%, n = 21 378). A combination of 
two or three antibiotic courses was given following 9.6% (n = 2277) 
and 0.03% (n = 8) of GE consultations with antibiotic treatment, re-
spectively. Thus, the 23 663 GE consultations with antibiotic treatment 
were linked to 25 956 antibiotic courses. Of these, the most frequently 
used ‘GE-relevant’ antibiotics were fluoroquinolones (28.9%), metro-
nidazole (26.8%) and macrolides (10.4%). β-Lactamase-sensitive 
penicillins, defined as ‘not GE relevant’ antibiotics in this study, were 
third most frequent, accounting for 10.8%.
For the ‘GE-relevant’ antibiotics, we found an increase from 
2006 to 12 in the number of courses of fluoroquinolones (128% 
increase), metronidazole (92.1% increase), sulfamethoxazole/tri-
methoprim (68.6% increase), tetracyclines (50.7% increase) and 
macrolides (64% increase), although there was a decrease in the 
number of courses of all these antibiotics from year 2012 to 2015, 
except for metronidazole (Table 2). For the ‘not GE-relevant’ anti-
biotics, an increase in the number of courses of penicillins with 
extended spectrum (70.8% increase) and β-lactamase-sensitive peni-
cillins (40% increase) was found for GE consultations during the 
10-year period (Table 2).
Metronidazole and fluoroquinolones (38.1%, n  =  868) rep-
resented the most frequent combination among the 2277 double 
courses, followed by metronidazole and extended spectrum peni-
cillins (27.3%, n  = 621), metronidazole and tetracyclines (15.8%, 
n = 359), and metronidazole and macrolides (9.5%, n = 116).
Discussion
Summary
We found that 1.8% of the GE consultations in Norwegian primary 
care resulted in treatment with antibiotics during the years 2006–15. 
Figure 1. Flow chart of gastroenteritis consultations with and without antibiotic 
treatment in primary care. Norway, 2006–15. aKUHR: Reimbursement 
claims database (the KUHR database). bNorPD: The Norwegian Prescription 
Database. cGE: gastroenteritis. dICPC-2: International Classification for 
Primary Care, version 2. eUTI: urinary tract infection.
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Young children were treated with antibiotics less frequent than older 
patients. Fluoroquinolones and metronidazole were most frequently 
used, followed by β-lactamase-sensitive penicillins and macrolides. 
The proportion of GE consultations resulting in antibiotic treatment 
increased until 2012, after which it declined. The same trend with 
initial increase and later reduction in treatment was not seen for 
metronidazole.
Strengths and limitations
The main strength of this study was the use of linked complete 
registry data from nearly all consultations in general practice and 
OOH services, and all courses of systemic antibiotics dispensed from 
pharmacies in Norway during a 10-year period. A limitation is that 
a part of the reimbursement claims from the 24-hour emergency 
services in Bergen (daytime consultations from workdays) are not 
included, leading to a minor underreporting of consultations in the 
OOH services. Furthermore, claims from electronic/telephone con-
sultations or home visits were not included in the current study. We 
expect that the use of telephone consultations is considerable, due 
to the nature of GE as a contagious disease. But these are prob-
ably dominated by requests for sick leave or similar administra-
tive purposes, and also more prone to misclassification of disease 
on reimbursement claims (26). However, telephone contacts may 
be used in the follow up of patients, and if these contacts result in 
the prescription of antibiotics, these courses would be missing in the 
current study. On the other hand, this may lead to an even greater 
underreporting of consultations without treatment. Hence, we do 
not think the study is subject to underestimation of antibiotic treat-
ment in Norwegian primary care.
Possible misclassification of the disease (GE) may challenge the 
internal validity. Our definition of a GE consultation including ‘D11 
Diarrhoea’ but not ‘D10 Vomiting’ is in line with the definition used 
by the Norwegian Syndromic Surveillance System (27), and a recent 
Dutch study on antibiotic treatment of GE in primary care (21). As 
a result, consultations for diarrhoea of other causes than GE are 
included, whereas GE consultations coded with ‘D10 Vomiting’ are 
missed. To our knowledge, studies on the validity of the diagnostic 
algorithm are lacking. Our calculation of treatment proportion was 
based on GE consultations, not GE cases or GE events. This implies 
that each case could have had several consultations during one GE 
event, leading to the possibility of an underestimation of the treat-
ment proportion.
The data on antibiotics were based on courses dispensed from 
pharmacies, not prescriptions. The indirect linking of dispensing to 
consultations may lead to possible misclassification of antibiotics as 
treatment for GE. We sought to minimize this by excluding courses 
linked to consultations with co-diagnoses more likely to represent 
the real indication for the prescription, as treatment for GE. We also 
excluded courses of UTI antibiotics as treatment for GE for the same 
reason. Still, we believe that our study will include dispensing of 
courses misclassified as GE treatment. This could be because relevant 
co-diagnoses were not registered in the consultation or the course 
might have been prescribed in consultations not included in the 
data material, such as telephone consultations, home visits, consult-
ations with doctors outside primary care, or in consultations taking 
place between the GE consultation and the dispensation. Antibiotic 
courses may also have been incorrectly defined as treatment for GE 
if the consultation was misclassified as a GE consultation.
Interpretation of results
The antibiotic treatment proportion in our study was lower (1.8%) 
than presented in literature from other high-income countries (18–22). 
This can be explained by low levels of bacterial and parasitic gastro-
intestinal infections in Norway, relative to viral infections (28,29). 
Other possible explanations can be that Norway generally has a low 
consumption of antibiotics (30), different health care seeking behav-
iour, or that GE cases with high risk of severe illness are hospitalized 
and thus not included in the study. The observed declining trend in anti-
biotic use in GE consultations after 2012 (16% reduction) coincides 
with an observed reduction in the total use of antibiotics (11% reduc-
tion) in Norway during the same period (17) and is in accordance with 
the goals of the Norwegian Action Plan (15).
Due to lack of clinical and microbiological data, we do not know 
the real indications for the antibiotic courses, and even less whether 
the treatment was empirical or specific. Our finding of relatively in-
frequent use of antibiotics in GE consultations indicates a restrictive 
use of antibiotics in the treatment of GE, as recommended by guide-
lines. The most frequently used antibiotics in the GE consultations 
in our study were fluoroquinolones and metronidazole, which are 
antibiotics shown to be commonly prescribed for gastrointestinal in-
fections in studies from primary care in the Netherlands, Switzerland 
and England (21,22,31). We have no explanations for the continuous 
increase in the use of metronidazole after 2012.
We found a lower prescription proportion among the 
youngest patients, a finding in line with a recent study from the 
Figure 3. Proportion of gastroenteritis consultations with antibiotic treatment 
by age category and type of service, Norway 2006–15. N = 1 279 867. DGP, 
daytime general practice; OOH, out-of-hours services.
Figure 2. Proportion of gastroenteritis consultations with antibiotic treatment 
by year and type of service, Norway 2006–15. N = 1 279 867. DGP, daytime 
general practice; OOH, out-of-hour services.
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Netherlands (21). This may be explained by higher GE consult-
ation frequency, and the increased likelihood of viral aetiology in 
younger patients (5).
The frequent use of the ‘not GE relevant’ β-lactamase-sensitive 
penicillins may be surprising as they are not suitable for treatment 
of any gastrointestinal infections, although they are strongly advo-
cated as the antibiotics of choice in treatment for several other in-
fections commonly seen in primary care. A study from the UK found 
β-lactamase-sensitive penicillins account for 1.3% of antibiotic pre-
scriptions for infections in the gastrointestinal tract, while a Dutch 
study of antibiotic treatment for GE in primary care did not include 
prescriptions of β-lactamase-sensitive penicillins (21). A  propor-
tion of the use of ‘not GE relevant’ antibiotics is probably related 
to misclassification of disease and/or antibiotic treatment for GE. 
Fifty percent of the treatments with β-lactamase-sensitive penicillins 
in the present study were linked to patients under 15 years of age. 
This may reflect a greater diagnostic challenge in consultations with 
children, with high levels of co-infections and uncertain symptoms 
and findings, leading to more misclassification of disease in these age 
categories. However, we cannot rule out the possibility that some 
doctors inappropriately prescribed the drug as a first-line drug with 
the intention to treat GE.
Previous studies from other European countries have indicated 
higher prescription rates in OOH services than in general practice 
for several infections (32–34), which corresponds to our finding of 
higher antibiotic treatment proportion in GE consultations in the 
OOH services.
The extensive use of CRP testing in Norwegian primary care, 
especially in consultations with patients with suspected infection 
and in OOH services, is described in previous studies from Norway 
(24,35,36). We do not have clinical information about the reason 
for our finding of extensive use of CRP testing in GE consultations 
with antibiotic treatment, nor the results of the tests, or if the tests 
affected the decision whether to prescribe antibiotics.
Conclusions
Antibiotic treatment is used in a very small proportion of GE consult-
ations in Norwegian general practice and OOH services. Although 
there was an overall increase in use during the study period, there 
was a reduction in overall use after year 2012. There was a reduction 
in use of fluoroquinolones and macrolides, but an increase in metro-
nidazole used also after 2012. The antibiotic treatment proportion 
of GE consultations was lowest in young children and increased with 
increasing age.
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TABLE S1 SUPPLEMENTARY. International Classification for Primary Care, version 2 
(ICPC-2) co-diagnoses (other than D11, D70 and D73) more likely representing the indication 
for prescription of systemic antibiotics in primary care. List by order of appearance in ICPC-
2. 
 
General and unspecified  
A78 Infectious disease other 
Eye 
F72  Blepharitis 
F73  Eye infection/inflammation other 
Ear 
H01  Ear pain 
H29  Ear symptom/complaint other 
H70  Otitis externa  
H71  Acute otitis media 
H72  Serous otitis media 
H73  Eustachian salpingitis 
H74  Chronic otitis media 
Cardiovascular  
K70  Infection of circulatory system 
K71  Rheumatic fever 
Musculoskeletal 
L70  Infections musculoskeletal system 
Neurological 
N71  Meningitis/encephalitis 
N73  Neurological infection other 
Respiratory 
R05 Cough 
R09 Sinus symptom/complaint  
R21 Throat symptom/complaint 
R25  Sputum/phlegm abnormal  
R71  Whooping cough 
R72  Strep throat 
R73  Boil/ascess nose 
R74  Upper respiratory infection acute 
R75  Sinusitis acute/chronic 
R76  Tonsillitis acute 
R77  Laryngitis/tracheitis 
R78  Acute bronchitis/bronchiolitis 
R79  Chronic bronchitis 
R81  Pneumonia 
R82 Pleurisy/pleural effusion 
R83  Respiratory infection other 
Skin 
S09  Infected finger/toe 
S10  Boil/carbuncle 
S11  Skin infection post-traumatic 
S13  Animal/human bite 
S73  Pediculosis/skin infestation other 
S76  Skin infection other 
S84  Impetigo 
S94 Ingrowing nail 
S96 Acne 
Urological 
U01  Dysuria/painful urination 
U07 Urine symptom/complaint other 
U13  Bladder symptom/complaint other 
U29 Urinary symptom/complaint other 
U70  Pyelonephritis 
U71  Cystitis 
U72  Urethritis 
U99  Urinary disease, other 
Pregnancy, Childbearing, Family Planning 
W29  Pregnancy symptom/complaint other 
W70  Puerperal infection/sepsis 
W71  Infection complicating pregnancy 
W94 Puerperal mastitis 
Female Genital 
X14 Vaginal discharge 
X15  Vaginal symptom/complaint other 
X17  Pelvis symptom/complaint female 
X23 Fear of sexually transmitted disease (f) 
X29 Genital symptom/complaint female other 
X70  Syphilis female 
X71  Gonorrhoea female 
X73  Genital trichomoniasis female 
X74  Pelvic inflammatory disease 
X92  Chlamydia infection genital female 
X99 Genital disease female, other 
Male Genital 
Y02 Pain in testis/scrotum 
Y03 Urethral discharge 
Y04  Penis symptom/complaint other 
Y05 Scrotum/testis symptom/complaint other 
Y06 Prostate symptom/complaint 
Y25 Fear of sexually transmitted disease male 
Y29 Genital symptom/complaint male other 
Y70  Syphilis male 
Y71  Gonorrhoea male 
Y73  Prostatitis/seminal vesiculitis 
Y74  Orchitis/epididymitis 
Y75  Balanitis 
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Abstract
Purpose Outbreaks of Campylobacter infection are common, but studies exploring the clinical features of acute illness in 
the outbreak setting are scarce in existing literature. The main purpose of the present study was to investigate the clinical 
features of self-reported acute illness in gastroenteritis cases during a large waterborne Campylobacter outbreak in Askøy 
municipality, Norway, in 2019.
Methods A web-based self-administered questionnaire, and invitation to participate was sent by the municipality of Askøy 
as text message to mobile phones using the municipality’s warning system to the inhabitants during the ongoing outbreak.
Results Out of 3624 participants, 749 (20.7%) were defined as cases, of which 177 (23.6%) reported severe gastroenteritis. 
The most common symptoms were loose stools (90.7%), abdominal pain (89.3%) and diarrhea (88.9%), whereas 63.8% 
reported fever, 50.2% joint pain and 14.2% bloody stools. Tiredness, a symptom non-specific to gastroenteritis, was the 
overall most common symptom (91.2%).
Conclusion About one in four of the cases reported symptoms consistent with severe gastroenteritis. We found more joint 
pain and less bloody stools than reported in published studies of laboratory confirmed campylobacteriosis cases. Tiredness 
was common in the current study, although rarely described in previous literature of acute illness in the outbreak setting.
Keywords Campylobacter infections · Disease outbreaks · Gastroenteritis · Waterborne diseases
Introduction
Campylobacter spp. is considered the most common bacte-
rial cause of gastroenteritis worldwide, as well as in Europe 
and Norway [1–3]. Approximately 3000 cases are reported 
annually in Norway, of which more than 50% are acquired 
abroad. The domestically infected cases are either sporadic 
or associated with smaller outbreaks, most commonly water-
borne [4, 5].
Common symptoms of gastroenteritis caused by Campy-
lobacter include loose stools, diarrhea (≥ 3 loose stools in 
24 h), nausea, vomiting, abdominal pain, bloody stools and 
fever, and the severity varies from mild and self-limiting 
symptoms (most common) to lethal disease [6–14]. Bloody 
stools and fever are considered markers of more severe 
infections [6, 13, 15, 16]. Several studies report symptoms 
and clinical features of campylobacteriosis, but these stud-
ies were predominantly published in the period from late 
1970s to 2000, and based mainly on surveillance data or 
sporadic cases of laboratory confirmed infection [7–12, 15, 
16]. Such cases represent a selected group that may differ 
from the total symptomatic population in the community 
[17, 18]. During large outbreaks of gastrointestinal infec-
tions, many cases are not tested and thus not registered. Most 
epidemiological studies on campylobacteriosis outbreaks 
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aim to identify the source of the outbreak and rarely include 
detailed descriptions of clinical features.
In some cases, campylobacteriosis is complicated with 
joint symptoms, or post-infectious neuropathy or irritable 
bowel syndrome (IBS) [8, 19–23]. Antibiotics are usually 
not needed in treatment of campylobacteriosis but may be 
useful in patients with severe disease [6, 15, 16, 24–27]. 
The burden of symptoms during an outbreak, including the 
extent of more severe disease is difficult to investigate since 
research cannot be planned in advance. Hence, comprehen-
sive baseline data from outbreaks are relatively rare.
In June 2019, there was a large community-wide water-
borne Campylobacter outbreak in the island municipality 
Askøy (population 29,500) in Norway. The outbreak was 
detected on 6 June 2019, and the outbreak investigation team 
consisting of the municipality of Askøy and the National 
Institute of Public Health’s (NIPH) later concluded that the 
drinking water had been contaminated by Campylobac-
ter jejuni sometime in late May 2019 [28]. The outbreak 
investigation findings were published in a report stating that 
more than 1500 inhabitants were ill during the outbreak [28]. 
Further, 67 patients were admitted to hospital and 2 deaths 
were related to the outbreak [28, 29]. Our group has long 
experience with research on clinical manifestations and com-
plications of gastroenteritis in an outbreak setting [30, 31] 
and established a large cohort study within days after the 
outbreak was acknowledged. The primary aim of this study 
was to describe the clinical features of self-reported acute 
gastroenteritis in a Campylobacter outbreak setting. Second-
ary aims were to investigate factors associated with severe 
gastroenteritis.
Methods
The current paper is based on data from the baseline survey 
out of totally four surveys in the Askøy Campylobacter Out-
break Study (ASCOS), a longitudinal cohort study following 
the outbreak. Households in Askøy received an invitation 
to participate in the study on 20 June 2019. Invitations and 
a webpage link to the survey were sent by the municipal-
ity of Askøy by one text message (SMS) to approximately 
16,000 mobile phones using the municipality’s warning sys-
tem, encouraging as many household members as possible 
to answer a questionnaire. Information was also presented 
in public meetings arranged by the municipality, on the 
municipality’s web site, and on posters in municipality and 
GP offices during the study period. Participants of all ages 
were included in the study. Consent from parents was needed 
for participants under the age of 16, and parents were asked 
to answer the questionnaire on behalf of younger children. 
Inclusion was closed on 1 July 2019.
Participants were asked if they were ill during the out-
break. Participants responding ‘yes’ were further asked 
about the acute disease (symptoms, duration of disease and 
perceived severity), management (use of health care services 
and medication) and consequences of the disease (absence 
from work or school). Participants answering ‘no’ or ‘uncer-
tain’ about acute illness did not receive these follow-up ques-
tions. Furthermore, all participants were asked if they had 
stayed continuously outside Askøy from 31 May up to the 
time for answering. The study population consists of all par-
ticipants who answered the question whether they were ill 
during the outbreak, excluding those reporting that they had 
not been in Askøy during the outbreak (Fig. 1).
We defined a ‘case’ as a participant who reported being 
ill with gastrointestinal symptoms during the outbreak, with 
symptom onset in the study period, and who experienced 
at least one of the following symptoms: loose stools, diar-
rhea, bloody stools, abdominal pain, vomiting and nausea. 
A ‘non-case’ was a participant reporting not being ill dur-
ing the outbreak or who reported being ill but did not fulfill 
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Fig. 1  Flow chart of inclusion and exclusion of the study popula-
tion, and of the cases, non-cases and the uncertain group, during the 
Campylobacter outbreak in Askøy
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the symptom criteria. Participants reporting that they were 
uncertain whether being ill during the outbreak or reported 
being ill and fulfilling the symptom criteria but with symp-
tom onset either before the study period or missing, were 
assigned to the ‘uncertain’ group (Fig. 1). The participants 
were not asked whether they had submitted stool samples for 
laboratory verification of Campylobacter infection, as the 
aim of the study was to study self-reported gastroenteritis in 
the population during the Campylobacter outbreak.
Participants were asked to report ‘perceived severity’ at 
the worst time point during the acute illness, using a scale 
from 1 (well) to 9 (life-threatening illness). In addition, we 
defined the outcome ‘severe gastroenteritis’ as cases report-
ing diarrhea for ≥ 5 days and at least one of either fever 
for ≥ 2 days or bloody stools. Cases not fulfilling these cri-
teria were defined as having ‘non-severe gastroenteritis’.
Duration of each of the following symptoms were speci-
fied by the predefined categories 1–2, 3–4 or 5–7 days, or 
1–2 or > 2 weeks: loose stools, diarrhea, bloody stools, 
nausea, vomiting, abdominal pain, fever, joint pain, tired-
ness and other symptoms, in addition to total duration of 
illness (number of days). Questions whether still being ill 
and whether each symptom was still present at the time of 
answering the survey were also included. The study ques-
tionnaire furthermore included questions about age (num-
ber of years), sex, educational level (elementary school, 
high school, and college/university), employment situa-
tion (student/pupil, worker, self-employed, unemployed, 
on welfare, and pensioner), marital status (single, married, 
divorced/separated, and widow/widower), household total 
income in Norwegian kroner (< 250,000, 250,000–499,999, 
500,000–749,999, 750,000–1,000,000, and > 1,000,000), 
self-reported previous diseases (diabetes, ulcerative coli-
tis, Crohn’s disease, esophagitis, irritable bowel syndrome 
(IBS), celiac disease, peptic ulcer, anxiety, depression, and 
rheumatic disease), intake of glasses with tap water dur-
ing the week prior to outbreak (0, 1–2, 3–5, > 5), intake of 
alcohol units during a normal week (number of units) and 
tobacco use (daily, sporadic, former daily smoker, and never 
smoked). Participants registered by their e-mail address, and 
were asked to voluntarily state their name, national identity 
number, telephone number and postal address for the pur-
pose of follow-up studies and possibility/opportunity to be 
invited into adjacent research studies. All personally identifi-
able information were deidentified prior to analyses.
Two different categorical variables were made for age, 
with three (0–24, 25–54 and ≥ 55 years) and 10 categories 
(0–4, 5–14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 
75–84 and ≥ 85 years), respectively. Duration of illness was 
categorized into 0–3, 4–7, 8–14 and ≥ 15 days. Alcohol units 
were categorized into the following six categories: 0, 1–2, 
3–5, 6–9, 10–14 and ≥ 15 units per week. Tobacco use was 
dichotomized. Analyses of alcohol and tobacco use were 
restricted to participants ≥ 16 years. Analyses of the vari-
ables educational level, employment situation and marital 
status, were restricted to participants ≥ 18 years. There was 
a high proportion of missing data for the variables age and 
sex in the baseline survey (29% and 26%, respectively), but 
we were able to add data from the follow-up surveys for 580 
and 507, respectively, giving a final of 13% missing age and 
12% missing sex information in the study population.
The data were collected online using SuveyXact by Ram-
bøll. All data have been stored, processed, and analyzed on 
the University of Bergen’s solution for secure processing of 
sensitive personal data in research (SAFE). The software R, 
StataSE 16.1 and Microsoft Excel for Windows 365 MSO 
have been used for processing and analyzing the data.
Descriptive statistics and Pearson’s x2-tests for associa-
tions were used to examine the distribution of different char-
acteristics by two outcomes: (1) cases, non-cases and the 
uncertain group, and (2) cases with severe gastroenteritis 
vs. non-severe gastroenteritis. For the outcome severe gas-
troenteritis vs non-severe gastroenteritis, we further explored 
the associations by estimating relative risks (RRs) with 95% 
confidence intervals using a modified Poisson regression 
model [32], adjusting for sex and age. Distribution of symp-
toms, illness duration, management, and short-term conse-
quences of the acute disease by sex and age were explored 
using descriptive statistics and Pearson’s x2-tests for asso-
ciations. Level of statistical significance was set at p < 0.05.
Results
During the study period, 8681 individuals accessed the web 
site, of which 3885 answered the questionnaire (Fig. 1). Of 
these, 261 were excluded because information about whether 
they had been ill was missing (n = 52) or because they had 
stayed outside Askøy (n = 209). In the study population of 
3624 participants, 749 (20.7%) were cases, 2417 (66.7%) 
non-cases and 458 (12.6%) were uncertain. Tables 1 and 2 
show the distribution of characteristics by cases, non-cases, 
and the uncertain group. The proportion of missing data for 
most variables, including sex and age, was highest in the 
uncertain group, followed by non-cases.
The most common symptoms reported by the 749 cases 
were tiredness (91.2%), loose stools (90.7%), abdominal 
pain (89.3%) and diarrhea (88.9%) (Table 3 and Fig. 2). 
Bloody stools (14.2%) and vomiting (24.0%) were the least 
frequently reported of the listed symptoms. Nausea and 
joint pain were reported by 74.0% and 50.2%, respectively, 
whereas 63.8% of the cases reported fever. There were no sex 
differences in the prevalence of symptoms, except for nau-
sea (78.9% in females vs. 67.7% in males, p < 0.01). Vom-
iting, fever, and tiredness were more commonly reported 
among the youngest and the oldest, compared to those aged 
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Table 1  Demographic 
characteristics of the study 
population, by cases with self-
reported gastroenteritis, non-
cases and the uncertain group, 
during the Campylobacter 
outbreak in Askøy
Distribution within characteristics is given by column unless stated by *
*Distribution by row, i.e., within study population
**Analyses restricted to participants ≥ 18 years
a P values from Pearson’s x2-test of association calculated from cross tables not including missing values 
and ‘uncertain group’
All Cases Non-cases Uncertain x2
n % n % n % n % pa
Total 3624 100 749 20.7* 2417 66.7* 458 12.6*
Sex 0.73
Male 1358 37.5 303 40.5 904 37.4 151 33.0
Female 1842 50.8 393 52.5 1209 50.0 240 52.4
Missing 424 11.7 53 7.1 304 12.6 67 14.6
Age range (years) 1–91 1–82 1–91 1–81
Age  < 0.01
0–4 22 0.6 6 0.8 12 0.5 4 0.9
5–14 30 0.8 8 1.1 14 0.6 8 1.7
15–24 236 6.5 72 9.6 136 5.6 28 6.1
25–34 483 13.3 112 15.0 296 12.2 75 16.4
35–44 701 19.3 159 21.2 460 19.0 82 17.9
45–54 691 19.1 171 22.8 427 17.7 93 20.3
55–64 477 13.2 101 13.5 328 13.6 48 10.5
65–74 445 12.3 52 6.9 349 14.4 44 9.6
75–84 82 2.3 10 1.3 67 2.8 5 1.1
 ≥ 85 2 0.1 0 0.0 2 0.1 0 0.0
Missing 455 12.6 58 7.7 326 13.5 71 15.5
Education level**  < 0.01
Elementary school 175 4.9 47 6.4 102 4.3 26 5.9
High school 1192 33.6 299 40.9 748 31.5 145 32.7
University/college 1431 40.4 290 39.7 981 41.4 160 36.0
Missing 748 21.1 95 13.0 540 22.8 113 25.5
Employment**  < 0.01
Student/pupil 146 4.1 34 4.7 95 4.0 17 3.8
Worker 1879 53.0 459 62.8 1193 50.3 227 51.1
Self-employed 94 2.7 20 2.7 62 2.6 12 2.7
Unemployed 89 2.5 22 3.0 52 2.2 15 3.4
On welfare 177 5.0 55 7.5 95 4.0 27 6.1
Pensioner 423 11.9 50 6.8 336 14.2 37 8.3
Missing 738 20.8 91 12.4 538 22.7 109 24.5
Houshold income 0.28
 < 250,000 86 2.4 23 3.1 51 2.1 12 2.6
250,000–499,999 393 10.8 89 11.9 254 10.5 50 10.9
500,000–749,999 609 16.8 130 17.4 388 16.1 91 19.9
750,000–1,000,000 683 18.8 171 22.8 437 18.1 75 16.4
 > 1,000,000 900 24.8 191 25.5 621 25.7 88 19.2
missing 953 26.3 145 19.4 666 27.6 142 31.0
Marital status**  < 0.01
Single 440 12.4 131 17.9 251 10.6 58 13.1
Married/cohabitant 2152 60.7 459 62.8 1446 61.0 247 55.6
Divorced/separated 153 4.3 40 5.5 93 3.9 20 4.5
Widow/widower 61 1.7 9 1.2 45 1.9 7 1.6
Missing 740 20.9 92 12.6 536 22.6 112 25.2
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25–54 years, whereas diarrhea was most common in age 
category 25–54 years. Bloody stools were most frequently 
reported by cases in the age category 0–24 years (25.6%); 
however, none of these was under the age of 15 years. In age 
category 25–54 years, bloody stools were reported in 14.7%, 
and in 8.6% of those 55 years or older.
Illness duration ranged from 0 to 24 days, with a median 
at 6 days (interquartile range: 4–9 days) (Table 3). Nine 
percent (n = 68) reported still being ill at the time of 
answering the survey (data not shown). Slightly more 
men than women reported illness duration of 0–3 days 
(16.8% vs. 14.0%, p = 0.04) and ≥ 15 days (5.6% vs. 3.8%, 
p = 0.04), while an illness duration of 8–14 days was more 
common in women than men (27.5% vs. 18.2%, p = 0.04). 
For illness duration of 4–7 days, no sex difference was 
observed. No significant differences across age were 
observed for the illness duration distribution (Table 3).
Table 2  Characteristics of the study population, by cases with self-reported gastroenteritis, non-cases, and the uncertain group, during the 
Campylobacter outbreak in Askøy
Distribution within characteristics is given by column unless stated by *
*Distribution by row, i.e., within study population
**Analyses restricted to participants ≥ 16 years old
a p values from Pearson’s x2-test of association calculated from cross tables not including missing values and ‘uncertain group’
b Average daily number of tap water glasses during week before outbreak
c Units of alcohol during a normal week
All Cases Non-cases Uncertain x2
n % n % n % n % pa
Total 3624 100 749 20.7* 2417 66.7* 458 12.6*
Tap water (glasses/day)b  < 0.01
0 225 6.2 21 2.8 183 7.6 21 4.6
1–2 963 26.6 158 21.1 664 27.5 141 30.8
3–5 1450 40.0 319 42.6 952 39.4 179 39.1
 > 5 976 26.9 247 33.0 612 25.3 117 25.5
missing 10 0.3 4 0.5 6 0.2 0 0.0
Alcohol (units/week)**c  < 0.01
0 1396 39.1 328 44.6 894 37.5 174 39.0
1–2 999 28.0 191 26.0 682 28.6 126 28.3
3–5 539 15.1 100 13.6 375 15.7 64 14.3
6–9 191 5.4 45 6.1 126 5.3 20 4.5
10–14 81 2.3 15 2.0 57 2.4 9 2.0
 ≥ 15 26 0.7 4 0.5 18 0.8 4 0.9
missing 336 9.4 52 7.1 235 9.8 49 11.0
Tobacco** 0.75
Yes 1602 44.9 322 43.8 1076 45.1 204 45.7
No 1895 53.1 401 54.6 1260 52.8 234 52.5
Missing 71 2.0 12 1.6 51 2.1 8 1.8
Previous diseases
None 1860 51.3 332 44.3 1329 55.0 199 43.4  < 0.01
Diabetes 142 3.9 22 2.9 105 4.3 15 3.3 0.09
Ulcerative colitis 50 1.4 6 0.8 34 1.4 10 2.2 0.20
Crohn’s disease 16 0.4 4 0.5 7 0.3 5 1.1 0.32
Oesophagitis 150 4.1 41 5.5 88 3.6 21 4.6 0.03
Irritable bowel syndrome 318 8.8 76 10.1 187 7.7 55 12.0 0.04
Celiac disease 35 1.0 12 1.6 17 0.7 6 1.3 0.02
Peptic ulcer 93 2.6 24 3.2 51 2.1 18 3.9 0.09
Anxiety 325 9.0 83 11.1 187 7.7 55 12.0  < 0.01
Depression 344 9.5 89 11.9 207 8.6 48 10.5  < 0.01
Rheumatic/inflammatory 207 5.7 54 7.2 121 5.0 32 7.0 0.02
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Each symptom’s duration turned out to fit into one of to 
two main patterns (Fig. 2): symptoms with (1) an approxi-
mate bell-shaped distribution where most cases reported 
either 3–4 days or 4–7 days duration (tiredness, loose stools, 
abdominal pain and diarrhea), and (2) symptoms most fre-
quently reported to last for either 1–2 days or 3–4 days with 
a subsequent decrease (nausea, fever, joint pain, vomiting 
and bloody stools). At the time of answering the survey, the 
proportions of cases reporting each symptom being ‘still 
present’ were: tiredness 15.9%, abdominal pain 9.0%, joint 
pain 8.5%, nausea 6.1%, diarrhea 6.0%, loose stools 5.9%, 
fever 1.3%, bloody stools 1.2%, and vomiting 0.5% (data 
not shown).
Paracetamol (62.8%) was the medication most frequently 
reported for treatment of the acute illness, followed by 
non-steroidal anti-inflammatory drugs (NSAIDs) (31.8%) 
(Table 3). Antibiotics use was reported by 2.8% (n = 21) of 
the cases, of which none were under the age of 15 years. 
Among the hospitalized cases, 30.3% (n = 10) reported 
antibiotics use, compared to 1.5% (n = 11) of those not hos-
pitalized. Loperamide was reported by 12.4% (n = 93) of 
the cases, most commonly used by those aged ≥ 55 years 
(21.5%) and least common in age category 0–24  years 
(8.1%). No cases under the age of 15 years reported use 
of loperamide. No significant differences between the sexes 
were observed for consulting a doctor, hospitalization, or 
any medication (data not shown).
Twenty-seven percent (n = 203) of the cases reported 
to have consulted a primary care doctor, which was more 
common among the youngest and oldest compared to the 
Table 3  Symptoms, management, and consequences of illness during the Campylobacter outbreak in Askøy, by age
Distribution within characteristics is given by column unless stated by *
*Distribution by row
** p value from Pearson’s x2-test of association calculated from cross tables not including missing values
Age category (years) All 0–24 25–54  ≥ 55 Missing x2
n % n % n % n % n % p**
Total 749 100 86 11.5* 442 59.0* 163 21.8* 58 7.7*
Symptoms
Loose stools 679 90.7 77 89.5 408 92.3 144 88.3 50 86.2 0.73
Diarrhea 666 88.9 70 81.4 408 92.3 138 84.7 50 86.2 0.04
Bloody stools 106 14.2 22 25.6 65 14.7 14 8.6 5 8.6  < 0.01
Nausea 554 74.0 71 82.6 321 72.6 120 73.6 42 72.4 0.12
Vomit 180 24.0 31 36.0 93 21.0 40 24.5 16 27.6 0.01
Abdominal pain 669 89.3 78 90.7 400 90.5 142 87.1 49 84.5 0.94
Fever 478 63.8 69 80.2 271 61.3 107 65.6 31 53.4  < 0.01
Joint pain 376 50.2 40 46.5 225 50.9 84 51.5 27 46.6 0.22
Tiredness 683 91.2 82 95.3 396 89.6 151 92.6 54 93.1  < 0.01
Illness duration (days) 0.43
0–3 120 16.0 13 15.1 75 17.0 16 9.8 16 27.6
4–7 316 42.2 40 46.5 196 44.3 53 32.5 27 46.6
8–14 171 22.8 22 25.6 108 24.4 33 20.2 8 13.8
 ≥ 15 33 4.4 6 7.0 16 3.6 10 6.1 1 1.7
Missing 109 14.6 5 5.8 47 10.6 51 31.3 6 10.3
Consulted doctor 203 27.1 31 36.0 109 24.7 53 32.5 10 17.2 0.01
Hospitalized 33 4.4 3 3.5 16 3.6 12 7.4 2 3.4 0.12
Absence school/work 414 55.3 59 68.6 281 63.6 46 28.2 28 48.3  < 0.01
Medication
None 184 24.6 21 24.4 109 24.7 42 25.8 12 20.7 0.03
Antibiotics 21 2.8 2 2.3 10 2.3 8 4.9 1 1.7 0.12
Loperamide 93 12.4 7 8.1 49 11.1 35 21.5 2 3.4  < 0.01
Tramadol 13 1.7 1 1.2 5 1.1 6 3.7 1 1.7 0.10
Codeine + paracetamol 41 5.5 3 3.5 24 5.4 8 4.9 6 10.3 0.39
Paracetamol 470 62.8 59 68.6 281 63.6 92 56.4 38 65.5 0.58
NSAIDs 238 31.8 41 47.7 156 35.3 21 12.9 20 34.5  < 0.01
Probiotics 167 22.3 17 19.8 101 22.9 35 21.5 14 24.1 0.02
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middle-aged cases (Table 3). Four percent had been admit-
ted to hospital, most commonly in the age category ≥ 55 years 
(Table 3). No cases below 15 years of age reported being 
admitted to hospital.
Twenty-four percent of the cases (n = 177) fulfilled the 
definition of ‘severe gastroenteritis’, and Supplementary 
tables 1 and 2 show the distribution and characteristics of these 
patients. There were significant positive associations between 
the outcome ‘severe gastroenteritis’, and the reported per-
ceived severity at the worst time point of the illness (Table 4). 
Furthermore, cases with severe gastroenteritis more often had 
been in contact with a primary care doctor or were hospital-
ized (Table 4).
Compared to the others, cases with severe gastroenteritis 
more often reported drinking > 5 glasses of tap water (41.2% 
vs 30.4%, p = 0.02), previous peptic ulcer (13.6% vs 2.3%, 
p = 0.01) and previous depression (16.9% vs 10.3%, p = 0.02) 
(Supplementary table 2). In the adjusted regression analyses, 
previous depression (RR: 1.61, 95% CI 1.16–2.24) and pre-
vious peptic ulcer (RR: 1.73, 95% CI 1.00–2.99) remained 
significant (Table 5). Further, age 55–64 years (RR: 0.62, 95% 
CI 0.41–2.46) and 35–44 (RR: 0.52, 95% CI 0.35–0.77), were 
associated with a lowered risk of severe gastroenteritis as com-
pared to the reference age category 45–54 years, although the 
RR for age 55–64 years was not significant in the unadjusted 
regression model.
Discussion
The typical gastroenteritis cases during the Campylobacter 
outbreak in our study were adults experiencing illness last-
ing for 4–7 days, with diarrhea, abdominal pain, and tired-
ness as the most common symptoms. About one in two 
of the cases reported fever or joint pain, whereas bloody 
stools and vomiting were less common. One in four of the 
cases fulfilled our definition of severe gastroenteritis. Risk 
factors associated with severe gastroenteritis were having 
depression or peptic ulcer prior to the outbreak, in addi-
tion to high consumption of tap water. Approximately 1 in 
4 had consulted a doctor, and 4% had been hospitalized.
A main strength of this study was that data were col-
lected during the acute phase of a large outbreak, which 
increases statistical power and reduces recall bias consid-
erably. This also constitutes a solid basis for follow-up 
studies of post-infectious complaints after the outbreak.
Invitations to participate in the study were sent by the 
municipality of Askøy as text message to mobile phones 
using the municipality’s warning system, an approach 
that had recently been used by the municipality and the 
Norwegian Institute of Public Health as part of their out-
break investigation [28]. Askøy municipality has 29,500 
inhabitants, and not all could be reached by this approach. 
Fig. 2  Duration of symptoms 
reported by cases with self-
reported gastroenteritis, during 
the Campylobacter outbreak in 
Askøy. N = 749
Tiredness Loosestools
Abdominal
pain Diarrhoea Nausea Fever Joint pain Vomit
Bloody
stools
1-2 days 104 127 122 140 180 231 105 129 53
3-4 days 144 203 162 222 151 148 103 23 34
5-7 days 158 204 200 176 119 61 77 13 7
1-2 weeks 137 98 106 82 53 27 36 9 7
≥2 weeks 88 34 58 26 38 9 37 4 1
Missing 52 13 21 20 13 2 18 2 4













 K. E. Emberland et al.
1 3
Information about age and sex were extracted from the 
national identity number, for those who had stated this. 
Using this procedure secured precise information for those 
who responded to this request, but resulted in missing data 
for those who did not want to give this information.
As many as 458 participants, 12.6% of the study popula-
tion, were uncertain whether they had been ill with acute 
gastrointestinal infection during the outbreak. Many persons 
in this group were likely having incident diffuse symptoms 
of other causes, but the size of the groups suggests that 
a fraction represents the less severe end of the spectrum 
of Campylobacter infection. As this group was not asked 
questions about symptoms, we could not categorize them as 
neither cases or non-cases based on such information. The 
uncertain group had the greatest proportion of missing data 
for most variables, representing a group with more uncer-
tain answers overall. Since the cases were not laboratory 
confirmed nor did we have variables to verify exposure to 
Campylobacter, such as detailed information on the drinking 
water supply, we could not investigate potential risk factors 
for developing campylobacteriosis during the outbreak.
Cases were not verified by a clinician’s diagnosis or 
by laboratory information. Using this population-based 
approach, we were able to investigate a broad spectrum of 
symptoms during the outbreak. However, this also intro-
duces some limitations. By use of a self-administered online 
questionnaire, we defined a ‘case’ based on the participants’ 
self-reported information about their geographical pres-
ence, onset of illness and symptoms related to the outbreak. 
There exist no common, symptom-based definitions of 
campylobacteriosis or gastroenteritis that are widely used 
for research purposes. Thus, our case definition was a modi-
fication of case definitions used in previous studies [33–36].
Our definition of ‘severe gastroenteritis’ was based on 
existing literature [6, 13, 15, 16], as well as clinical experi-
ences and expertise among members in the research group, 
and aimed to capture a set of symptoms which indicated 
a greater extent of both local inflammation in the bowels 
(diarrhea for ≥ 5 days or bloody stools) and more generalized 
disease (fever > 2 days). We observed an association between 
‘severe gastroenteritis’, and perceived severity at the worst 
time point during the illness, and health care use, which to 
some extent suggests validity to the definition.
Population-based cohort studies describing the clinical 
features of Campylobacter infection during an ongoing out-
break, are scarce in existing literature. The proportion of 
Table 4  Health care seeking 
and perceived severity of illness 
during the Campylobacter 
outbreak in Askøy, by cases 
with severe or non-severe 
gastroenteritis
Distribution within characteristics is given by column unless stated by *
*Distribution by row
a p values from Pearson’s x2-test of association calculated from cross tables between cases with non-severe 
and severe gastroenteritis
b Self-reported perceived severity at worst time point of illness. Scale from 1 (well) to 9 (life threatening)
All Non-severe Severe x2
n % n % n % pa
Total 749 100 572 76.4* 177 23.6*
Contacted doctor  < 0.01
Yes 203 27.1 117 20.5 86 48.6
No 539 72.0 450 78.7 89 50.3
Uncertain 5 0.7 3 0.5 2 1.1
Missing 2 0.3 2 0.3 0 0.0
Hospitalized 0.01
Yes 33 4.4 16 2.8 17 9.6
No 715 95.5 555 97.0 160 90.4
Missing 1 0.1 1 0.2 0 0.0
Perceived  severityb  < 0.01
1 well 8 1.1 6 1.0 2 1.1
2 39 5.2 37 6.5 2 1.1
3 125 16.7 118 20.6 7 4.0
4 152 20.3 133 23.3 19 10.7
5 157 21.0 133 23.3 24 13.6
6 160 21.4 99 17.3 61 34.5
7 83 11.1 37 6.5 46 26.0
8 21 2.8 8 1.4 13 7.3
9 life threatening 4 0.5 1 0.2 3 1.7
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children with acute gastroenteritis was lower in our study 
compared to previous studies of Campylobacter infections 
[9, 10]. Selection bias may have led to underrepresentation 
of the elderly and children. The latter is suggested by our 
previous finding of 17 patients under the age of 16 years 
in the study that characterized hospitalized patients during 
the same outbreak [29], whereas the present study found no 
hospitalized cases under the age of 15 years.
Our finding of diarrhea and abdominal pain as the most 
common, and bloody stools and vomiting as the least com-
mon symptoms of acute gastroenteritis in the outbreak set-
ting, is in line with previous literature on Campylobacter 
infection [8–10, 14, 34, 37]. The proportion of cases report-
ing bloody stools were 14% in the present study, which is 
higher compared to the findings in two previous outbreak 
investigation studies: a population-based study of an out-
break in Røros, Norway (2%) [34], and in a study of cases 
included among patients seeking health care services (of 
which 16% were laboratory confirmed) during an outbreak 
in Finland (4%) [37]. The two previously published studies 
of the Askøy outbreak; NIPH’s population-based outbreak 
investigation study (6%) [34] and the study of hospitalized 
cases (9%), also found lower proportions of bloody stools 
than the present study [28, 29]. Higher proportions of bloody 
stools, ranging from 30 to 58%, are reported in a study of 
laboratory confirmed cases in general practice in the Neth-
erlands [9], of sporadic notified cases in Norway [10], of 
laboratory confirmed cases aged 0–14 years in an outbreak 
Table 5  Severe gastroenteritis 
by characteristics, during the 
Campylobacter outbreak in 
Askøy. Unadjusted and adjusted 
relative risks (RR) with 95% 
confidence intervals (CIs)
a Adjusted for sex, age, intake of tap water, peptic ulcer and depression
b Average daily number of tap water glasses during week before outbreak
NA not applicable
Unadjusted Adjusteda
RR CI RR CI
Sex
Male 1.14 0.89—1.48 1.29 1.00—1.66
Female Reference Reference
Age group (years)
0–4 1.02 0.32—3.22 1.23 0.35—4.37
5–14 0.38 0.06—2.42 0.35 0.05—2.26
15–24 0.89 0.59—1.36 0.77 0.50—1.20
25–34 0.85 0.59—1.22 0.76 0.52—1.11
35–44 0.54 0.36—0.80 0.52 0.35—0.77
45–54 Reference Reference
55–64 0.67 0.43—1.02 0.62 0.41—0.94
65–74 0.65 0.37—1.14 0.62 0.36—1.10
75–84 0.92 0.35—2.42 0.89 0.32—2.46
 ≥ 85 NA NA
Tap water (glasses/day)b
0 0.83 0.34—2.06 0.76 0.32—1.81
1–2 0.72 0.48—1.08 0.73 0.49—1.09
3–5 Reference Reference




Ulcerative colitis 2.14 0.95—4.81
Crohn’s disease 1.06 0.19—5.81
Oesophagitis 1.37 0.86—2.19
Irritable bowel syndrome 1.26 0.86—1.84
Celiac disease 0.35 0.05—2.29
Peptic ulcer 2.00 1.27—3.16 1.73 1.00—2.99
Anxiety 1.32 0.92—1.89
Depression 1.51 1.09—2.09 1.61 1.16—2.24
Rheumatic/inflammatory 0.94 0.56—1.57
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in Greece [38], and notified cases in Australia, Canada and 
the United states [14]. The latter study also reported associa-
tion between age and bloody stools, in line with our find-
ing, although their proportions of bloody diarrhea among 
the youngest (59% in age < 5 years, 49% in 5–24 years) 
were higher than in our study (25.6% aged < 25 years, but 
none < 15 years). The reason for lower proportions of bloody 
stools reported in outbreak studies, including the present 
study, may be that they capture a broader scope of clinical 
features than represented by the laboratory confirmed cases. 
The corresponding low proportion of bloody stools observed 
in the study of hospitalized patients during the Askøy out-
break, can be explained by a possible lowered threshold for 
referral due to fatal outcome in the initial phase of the out-
break, thus leading to hospitalization of less severe cases 
[29]. However, virulence factors associated with bloody 
stools of the particular strain of Campylobacter jejuni can-
not be ruled out [29].
Joint pain was more common in our study compared to 
a Norwegian study of sporadic campylobacteriosis from 
1992 (50% vs. 27%) [10], but otherwise seems to be scarcely 
described in existing literature as a symptom during the 
acute phase of Campylobacter infection. Tiredness was not a 
case-defining symptom, but still the most frequently reported 
in our study. We could not find descriptions of tiredness in 
published studies, probably because it is unspecific to gastro-
enteritis or Campylobacter infection. However, documenting 
the baseline level of the symptom at the time of the outbreak 
is useful to follow-up studies of post-infectious complaints, 
and should perhaps be investigated further in future out-
breaks. Our findings of more common joint pain and less 
bloody stools in these cases with self-reported gastroenteritis 
than previously reported in studies of laboratory confirmed 
Campylobacter cases, may reflect that the population-based 
approach may capture a broader spectrum of clinical fea-
tures of acute gastroenteritis during in the Campylobacter 
outbreak setting.
Median duration of illness observed in our study (6 days) 
is in line with what is commonly reported in previous studies 
(5–6 days) [14, 34, 37], except for the Norwegian study of 
sporadic cases from 1992 reporting median 11 days dura-
tion [10].
A total of 3%, none under the age of 15 years, and 30% of 
the hospitalized cases in the current study received antibiotic 
treatment. The study of hospitalized patients during the same 
outbreak found that one in two of children and one in ten of 
adults received antibiotics [29]. Kapperud et al. reported in 
1992 that 16% of 135 sporadic laboratory confirmed cases in 
Norway were treated with antibiotics [10], and White et al. 
2019 reported an antibiotic treatment proportion of 35% in 
culture confirmed cases in Australia, Canada and the United 
States [14], although neither discriminated between hospital-
ized and non-hospitalized treatment proportions. Our finding 
of low antibiotic treatment proportion is concordant with 
the recommendations, and with a generally cautious policy 
regarding use of antibiotics in Norway [6, 24, 25, 39].
Risk factors associated with severe gastroenteritis were 
high consumption of tap water, having depression or peptic 
ulcer prior to the outbreak, whereas being in the age cat-
egory 35–44 seemed to be protective. As the outbreak was 
waterborne, the association between high consumption of 
tap water and severe gastroenteritis probably indicates a 
dose–response relationship. Psychological comorbidity has 
previously been shown to increase susceptibility to develop 
infectious gastroenteritis [23], but bias may lead to reporting 
of more severe symptoms in cases with depression, as the 
symptom pressure can be perceived as more burdensome 
in this patient group. However, this effect should have been 
reduced because the outcome ‘severe gastroenteritis’ in these 
analyses was defined by reported symptoms rather than the 
cases’ own assessment of perceived illness severity. Peptic 
ulcer as a risk factor for severe illness is reasonable, as a gas-
trointestinal disease, and not least presumably often treated 
with anti-acidic medication which may cause vulnerability 
to a more severe illness.
Conclusions
We present clinical features of self-reported acute gastro-
enteritis in a population during a large waterborne outbreak 
of Campylobacter infection. The most common symptoms 
were loose stools, abdominal pain, and diarrhea. About 
one in four of the cases reported symptoms consistent with 
severe gastroenteritis. Although not a gastroenteritis specific 
symptom, tiredness was the overall most common symp-
tom, but is rarely described in previous studies of acute 
campylobacteriosis.
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Supplementary table 1. Demographic characteristics of cases with self-reported gastroenteritis, by severe 
and non-severe gastroenteritis, during the campylobacter outbreak in Askøy. 
   
All Non-severe Severe x2 
  
n % n % n % pb 
Total 749 100 572 76.4* 177 23.6* 
 
Sex 
      
0.31 
 
male 303 40.5 221 38.6 82 46.3 
 
 
female 393 52.5 300 52.4 93 52.5 
 
 
missing 53 7.1 51 8.9 2 1.1 
 
Age range (years) 1-82 1-82 1-79 
 
Age 
      
0.11 
 
0-4 6 0.8 4 0.7 2 1.1 
 
 
5-14 8 1.1 7 1.2 1 0.6 
 
 
15-24 72 9.6 51 8.9 21 11.9 
 
 
25-34 112 15.0 81 14.2 31 17.5 
 
 
35-44 159 21.2 131 22.9 28 15.8 
 
 
45-54 171 22.8 115 20.1 56 31.6 
 
 
55-64 101 13.5 79 13.8 22 12.4 
 
 
65-74 52 6.9 41 7.2 11 6.2 
 
 
75-84 10 1.3 7 1.2 3 1.7 
 
 
≥85 0 0.0 0 0.0 0 0.0 
 
 
missing 58 7.7 56 9.8 2 1.1 
 
Marital status** 
       
 
single 131 17.9 92 16.5 39 22.4 0.50 
 
married/cohabitant 459 62.8 343 61.6 116 66.7 
 
 
divorced/separated 40 5.5 31 5.6 9 5.2 
 
 
widow/widower 9 1.2 8 1.4 1 0.6 
 
 
missing 92 12.6 83 14.9 9 5.2 
 
Education level** 
      
0.31 
 
elementary school 47 6.4 36 6.5 11 6.3 
 
 
high school 299 40.9 214 38.4 85 48.9 
 
 
university/college 290 39.7 223 40.0 67 38.5 
 
 
missing 95 13.0 84 15.1 11 6.3 
 
Employment** 
      
0.06 
 
student/pupil 34 4.7 22 3.9 12 6.9 
 
 
worker 459 62.8 346 62.1 113 64.9 
 
 
self employed 20 2.7 16 2.9 4 2.3 
 
 
unemployed 22 3.0 16 2.9 6 3.4 
 
 
on welfare 55 7.5 33 5.9 22 12.6 
 
 
pensioner 50 6.8 42 7.5 8 4.6 
 
 
missing 91 12.4 82 14.7 9 5.2 
 
         
Household income 
      
0.44 
 
< 250000 23 3.1 15 2.6 8 4.5 
 
 
250000-499999 89 11.9 71 12.4 18 10.2 
 
 
500000-749999 130 17.4 91 15.9 39 22.0 
 
 
750000-1000000 171 22.8 129 22.6 42 23.7 
 
 
> 1000000 191 25.5 142 24.8 49 27.7 
 
 
missing 145 19.4 124 21.7 21 11.9 
 
Distribution within characteristics is given by column unless stated by *. 
* Distribution by row. 
** Analyses restricted to participants ≥18 years old. 





Supplementary table 2. Characteristics of cases with self-reported gastroenteritis, by severe and non-severe 
gastroenteritis, during the campylobacter outbreak in Askøy. 
   
All Non-severe Severe x2 
  
n % n % n % pa 
Total 749 100 572 76.4 177 23.6 
 
Tap water (glasses/day)b 
      
0.02 
 
0 21 2.8 17 3.0 4 2.3 
 
 
1-2 158 21.1 132 23.1 26 14.7 
 
 
3-5 319 42.6 246 43.0 73 41.2 
 
 
>5 247 33.0 174 30.4 73 41.2 
 
 
missing 4 0.5 3 0.5 1 0.6 
 
Alcohol (units/week)**c 
      
0.44 
 
0 328 44.6 255 45.5 73 42.0 
 
 
1-2 191 26.0 151 26.9 40 23.0 
 
 
3-5 100 13.6 75 13.4 25 14.4 
 
 
6-9 45 6.1 30 5.3 15 8.6 
 
 
10-14 15 2.0 11 2.0 4 2.3 
 
 
≥15 4 0.5 4 0.7 0 0.0 
 
 
missing 52 7.1 35 6.2 17 9.8 
 
Tobacco** 
      
0.23 
 
yes 322 43.8 240 42.8 82 47.1 
 
 
no 401 54.6 314 56.0 87 50.0 
 
 
missing 12 1.6 7 1.2 5 2.9 
 
Previous diseases 
       
 
none 332 44.3 261 45.6 71 40.1 0.20 
 
diabetes 22 2.9 14 2.4 8 4.5 0.15 
 
ulcerative colitis 6 0.8 3 0.5 3 1.7 0.13 
 
Crohns disease 4 0.5 3 0.5 1 0.6 0.10 
 
oesophagitis 41 5.5 28 4.9 13 7.3 0.21 
 
IBS 76 10.1 54 9.4 22 12.4 0.25 
 
celiac disease 12 1.6 11 1.9 1 0.6 0.21 
 
peptic ulcer 37 4.9 13 2.3 24 13.6 0.01 
 
anxiety 83 11.1 58 10.1 25 14.1 0.14 
 
depression 89 11.9 59 10.3 30 16.9 0.02 
 
rheumatic/inflammatory 54 7.2 42 7.3 12 6.8 0.80 
Distribution within characteristics is given by column unless stated by *. 
* Distribution by row. 
** Analyses restricted to participants ≥16 years old. 
a P-values from Pearson’s x2-test of association calculated from cross tables that do not include missing values.  
b Average daily number of tap water glasses during week before outbreak. 










Paper version of web-based 
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Spørreundersøkelse om mageinfeksjonutbruddet på Askøy i juni 2019
 
Takk til alle som svarte på Askøy kommune og Folkehelseinstituttet sin spørreundersøkelse nylig. Det gav nyttig informasjon om
utbruddet, og bidro til å vurdere tiltakene som ble iverksatt. 
Vi ønsker at ALLE som mottar denne henvendelsen svarer, også om du IKKE var syk under utbruddet. Undersøkelsen tar ca 12
minutter å gjennomføre. Vi setter pris på om du svarer så snart som mulig, men innen 30. juni.
I denne undersøkelsen spør vi etter helse- og personoppysninger som er nyttige for forskningsformål, blant annet for å følge opp
Askøys befolkning i tiden etter utbruddet.
Dette er en oppfølging av den undersøkelsen, samtidig med en forespørsel til deg om å delta i et forskningsprosjekt der Universitetet
i Bergen i samarbeid med Askøy kommune, Folkehelseinstituttet, NORCE Norwegian Research Centre og Helse Bergen undersøker
omfanget og alvorlighetsgraden av mageinfeksjonsutbruddet på Askøy og konsekvensene for folks helse på sikt. Prosjektet vil kunne
bidra til å danne grunnlag for bedre behandling og oppfølging av pasienter rammet av slike infeksjoner.
Trykk HER for å lese utdypende informasjonsskriv med følgende tema (blir åpnet i eget vindu).
Hva innebærer prosjektet?
Mulige fordeler og ulemper
Frivillig deltakelse og mulighet for å trekke sitt samtykke




Du beveger deg frem og tilbake i spørreskjemaet ved å klikke på pilene nederst på siden. Svarene dine mellomlagres i systemet og
du kan til enhver tid avbryte din besvarelse, for senere å gå inn i spørreskjemaet og fullføre besvarelsen ved å klikke på linken i e-
posten. De fleste spørsmål er frivillige å svare på. 
Dersom du har spørsmål til prosjektet kan du ta kontakt med.
Prosjektleder og professor Guri Rørtveit, tlf. 55 58 61 41, e-post guri.rortveit@uib.no.
Personvernombud ved Universitetet i Bergen er:
Janecke Veim, e-post janecke.veim@uib.no
Har du fylt 16 år?
Ja
Nei
Vi vil gjerne at du fyller ut spørreskjemaet, men siden du er under 16 år, krever norsk lov at vi får skriftlig samtykke av en av dine
foresatte. Vennligst trykk her for å laste ned samtykkeskjema som du kan fylle ut og returnere til oss enten ved å
1) skanne og sende på mail til prosjektleder og professor Guri Rørtveit, tlf. 55 58 61 41, e-post guri.rortveit@uib.no.
eller
 
2) sende som brevpost til
Universitetet i Bergen




Vennligst bekreft at du har samtykke fra en av dine foresatte til å fortsette undersøkelsen
Ja, jeg har samtykke
Nei, jeg har ikke samtykke
Svar på spørsmålene i denne undersøkelsen regner vi som et samtykke til at vi kan bruke svarene dine til forskning. Dersom du ikke
ønsker å delta kan du lukke nettleseren nå.




Når ble du syk under dette utbruddet?
 
Angi hvilke symptomer du har hatt, og i så fall antall dager symptomet varte. Hvis du fortsatt opplever symptomer kan du oppgi
dette. Hvis du ikke har opplevd et symptom, kan du svare "ingen symptom".
 Nei, ikke hatt dette symptomet 1-2 dager 3-4 dager 5-7 dager 1-2 uker Over 2 uker Fortsatt tilstede
Løs/vandig avføring









Hvis du hadde andre symptomer, vennligst angi hvilke (adskilt med komma)
Hvor mange dager var du syk totalt sett?
 
Hvor syk var du da du var på det sykeste?


















Ble du innlagt i sykehus for den aktuelle sykdommen?
Ja
Nei
Har du hatt fravær fra jobb, skole eller barnehage i perioden grunnet mageinfeksjonsutbruddet?
Ja
Ja, men fraværet skyldes ikke mageinfeksjonutbruddet
Nei
Ikke relevant
Er du fremdeles fraværende fra jobb, skole eller barnehage?
Ja
Nei
Angi periode du var fraværende fra jobb eller skole
Fra dato  
Til dato  
Har du brukt medikamenter for mageinfeksjonen under utbruddet?








Probiotika, f.eks. Biola, Cultura, Idoform
Brukte du andre medisiner for mageinfeksjonen?
Skriv hvilke medisiner, skilt med komma  
Du får noen ekstra spørsmål fra Folkehelseinstituttet siden svarte at du ble syk etter 12. juni
Hva tror du selv er årsaken til sykdommen?




Er vedkommende medlem av samme husholdning som deg?
Nei
Ja









Har du fulgt kokeanbefalingene siden 13. juni 2019?
Ja
Nei
Hvorfor valgte du ikke å følge kokeanbefalingen(e)? Flere kryss mulig.
Glemte det
Vannet var klart og ok
Kjøpte vann på flaske
Tenkte det var liten eller ingen risiko for å bli syk
Drikker ikke/generelt lite vann fra springen
Vet ikke/husker ikke














I hvor mange dager drakk du vann fra springen etter at du ble syk?
 

















Hvor mange enheter alkohol drikker du vanligvis i løpet av en uke (1 enhet: 0,33l øl, 1 glass vin, 4cl brennevin)?
 


















Ved avkryssing av "andre" over, vennligst skriv hvilke, skilt med komma
Hvilke av disse medisinene har du brukt siste måned? Flere kryss mulig.
Ingen
Magesyredempende medisiner (eks: Nexium/esomeprazol, lansoprazol, Losec/omeprazol, Somac/pantoprazol, novalucid, titralac, Zantac/ranitidin, cimetidine)
Immundempende medisin (eks: prednisolon, imurel, methotrexate, cellegift)
Probiotika (eks: Biola, Cultura, Idoform)
Medisin mot diaré (eks imodium, loperamid)
Kvalmedempende(eks: afipran/metoklopramid, zofran/ondansetron)
Betennelsesdempende (eks: ibux, ibuprofen, voltaren/diklofenac, celebra/celecoxib, napren/naproxen, Brexidol/piroxicam)
Paracet, Paracetamol/panodil
Acetylsalisylsyre (eks: Albyl-E, Dispril, Aspirin)
Antibiotika
Vi ønsker nå at du svarer på noen spørsmål om din helse fra før utbruddet startet, det vil si før 31.mai.
I løpet av siste tre måneder før utbruddet, hvor ofte har du hatt ubehag eller smerter noe sted i magen?
Aldri
Mindre enn 1 dag i måneden
En dag i måneden
2-3 dager i måneden
En dag i uka
Mer enn en dag i uka
Hver dag
I løpet av siste tre måneder før utbruddet, hvor ofte hadde du smerter og ikke bare ubehag noe sted i magen?
Aldri
Mindre enn 1 dag i måneden
En dag i måneden
2-3 dager i måneden
En dag i uka
Mer enn en dag i uka
Hver dag
For kvinner: Har du kun hatt dette ubehaget eller smerten i forbindelse med menstruasjons-blødning og ikke til andre tider?
Nei
Ja
Ikke aktuelt fordi jeg ikke har menstruasjon
Har du hatt dette ubehaget eller smerten i 6 måneder eller lenger?
Nei
Ja




Det meste av tiden
Alltid




Det meste av tiden
Alltid




Det meste av tiden
Alltid




Det meste av tiden
Alltid




Det meste av tiden
Alltid
I løpet av de siste tre måneder før utbruddet, hvor ofte har du hatt løs, grøtete eller vandig avføring?
Sjelden/aldri
Ca. 25% av tiden
Ca. 50% av tiden
Ca. 75% av tiden
Alltid, 100% av tiden
I løpet av siste tre måneder før utbruddet, hvor ofte har du hatt hard eller klumpete avføring?
Sjelden/aldri
Ca. 25% av tiden
Ca. 50% av tiden
Ca. 75% av tiden
Alltid, 100% av tiden





Hadde du leddplager i løpet av den siste måneden før utbruddet?
Smerter i ledd
Nei
Ja, i 1 ledd, hvilket  
Ja, i flere ledd, hvilke  
Hevelse i ledd
Nei
Ja, i 1 ledd, hvilket  
Ja, i flere ledd, hvilke  
Stivhet i ledd
Nei
Ja, i 1 ledd, hvilket  
Ja, i flere ledd, hvilke  
Har du revmatisk sykdom?
Nei
Ja, evt hvilken  
Usikker
Slitenhet
Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd den siste måneden FØR utbruddet. Vennligst besvar ALLE
spørsmålene ved å krysse
Hadde du problemer med at du følte deg sliten?
Mindre enn vanlig
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Trengte du mer hvile?
Nei, mindre enn vanlig
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Følte du deg søvnig eller døsig?
Mindre enn vanlig
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Hadde du problemer med å komme i gang med ting?
Mindre enn vanlig
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Manglet du overskudd?
Ikke i det hele tatt
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Hadde du redusert styrke i musklene dine?
Ikke i det hele tatt
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig




Mye mer enn vanlig




Mye mer enn vanlig
Forsnakket du deg i samtaler?
Mindre enn vanlig
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Var det vanskeligere å finne det rette ordet?
Mindre enn vanlig
Ikke mer enn vanlig
Mer enn vanlig
Mye mer enn vanlig
Hvordan var hukommelsen din?
Bedre enn vanlig
Ikke verre enn vanlig
Verre enn vanlig
Mye verre enn vanlig
Når du følte deg sliten før utbruddet, omtrent hvor lenge hadde det vart?
Mindre enn en måned
Mellom en og seks måneder
Seks måneder eller mer
Når du følte deg sliten før utbruddet, omtrent hvor mye av tiden kjente du det?
25 % av tiden
50 % av tiden




Spørsmålene under besvares i antall dager per uke du har opplevd følgende problemer, hvor 0 er ingen dager i løpet av en uke, 7 er
alle dager i løpet av en uke.
I løpet av de siste tre månedene, hvor mange dager per uke har du:
 0 1 2 3 4 5 6 7
Brukt mer enn 30 minutter for å sovne etter at lysene ble slukket?
Vært våken mer enn 30 minutter innimellom søvnen?
Våknet mer enn 30 minutter tidligere enn du har ønsket uten å få sove igjen?
Følt deg for lite uthvilt etter å ha sovet?
Vært så søvnig/trett at det har gått ut over skole/jobb eller privatlivet?
Vært misfornøyd med søvnen din?






Bruker du sovemedisiner på resept?
Nei
Av og til
1-2 dager per uke
3-6 dager per uke
Daglig
Trivsel og helse
Her kommer noen spørsmål om hvordan du føler deg. For hvert spørsmål setter du kryss for ett av de fire svarene som beskriver dine
følelser den siste uken. Ikke tenk for lenge på svaret - de spontane svarene er best.
Jeg føler meg nervøs og urolig
Mesteparten av tiden
Mye av tiden
Fra tid til annen
Ikke i det hele tatt
Jeg gleder meg fortsatt over ting, slik jeg pleide før
Avgjort like mye
Ikke fullt så mye
Bare lite grann
Ikke i det hele tatt
Jeg har en urofølelse, som om noe forferdelig vil skje
Ja, og noe svært ille
Ja, ikke så veldig ille
Litt, bekymrer meg lite
Ikke i det hele tatt
Jeg kan le og se det morsomme i situasjoner
Like mye som før
Ikke like mye som før
Avgjort ikke som før
Ikke i det hele tatt




En gang i blant









Ikke i det hele tatt
Jeg føler meg som om alt går langsommere
Nesten hele tiden
Svært ofte
Fra tid til annen
Ikke i det hele tatt
Jeg føler meg urolig, som om jeg har sommerfugler i magen
Ikke i det hele tatt
Fra tid til annen
Ganske ofte
Svært ofte
Jeg bryr meg ikke lenger om hvordan jeg ser ut
Ja, jeg har sluttet å bry meg
Ikke som jeg burde
Kan hende ikke nok
Bryr meg som før
Jeg er rastløs, som om jeg stadig må være aktiv
Uten tvil svært mye
Ganske mye
Ikke så veldig mye
Ikke i det hele tatt
Jeg ser med glede frem til hendelser og ting
Like mye som før
Heller mindre enn før
Avgjort mindre enn før
Nesten ikke i det hele tatt
Jeg kan plutselig få en følelse av panikk
Uten tvil svært ofte
Ganske ofte
Ikke så veldig ofte
Ikke i det hele tatt
Jeg kan glede meg over gode bøker, radio og TV
Ofte
Fra tid til annen
Ikke så ofte
Svært sjelden
Vi ønsker flere samtykker fra deg for å kunne få best mulig kunnskap om utbruddet og konsekvensene av dette. Dette vil kunne bidra
til bedre oppfølging av de som ble rammet.
Jeg samtykker til: 
Vennligst kryss av ved alle du samtykker til
innhenting av opplysninger om meg hos fastlege, legevakt eller sykehus (evt. sykehjem)
videre analyser av allerede innhentede prøver
at det kan tas kontakt med meg for å få tatt nye prøver
at data om meg kan kobles til helseregistre som nevnt i informasjonsskrivet
Lenke til infoskriv her.










Hva er navnet ditt?
Fornavn  
Etternavn  
Hva er ditt fødsels- og personnummer?
ddmmååxxxxx (f.eks. 03129811111)
 
Hva er din alder?
 
Hva er ditt kjønn?
Mann
Kvinne

























Hvor mange voksne personer (18 år eller eldre) bor i din husstand?
 
Hvor mange barn/ungdommer (yngre enn 18 år) bor i din husstand?
 
Hva er samlet årsinntekt for husstanden?
Mindre enn 250 000
250 000 - 499 999
500 000 - 749 999
750 000 - 1 000 000
Over 1 000 000
Du har svart at du er under 16 år og at du ikke har samtykke av en av dine foresatte til å delta i undersøkelsen. Undersøkelsen
avsluttes derfor.
Når du trykker "avslutt" blir svaret ditt lagret og du blir tatt med til informasjonssiden for denne undersøkelsen.
Takk for at du tok deg tid til å svare på undersøkelsen.
Når du trykker "avslutt" blir svaret ditt lagret og du blir tatt med til informasjonssiden for denne undersøkelsen.
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